Search Result
Results for "
metabolic
" in MCE Product Catalog:
5041
Inhibitors & Agonists
127
Biochemical Assay Reagents
721
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
-
- HY-17623S
-
-
- HY-W010382
-
|
Oxaloacetic acid
2-Oxosuccinic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Oxaloacetic acid (2-Oxosuccinic acid) is a metabolic intermediate involved in several ways, such as citric acid cycle, gluconeogenesis, the urea cycle, the glyoxylate cycle, amino acid synthesis, and fatty acid synthesis.
|
-
- HY-W251393
-
-
- HY-101972
-
|
AZ-PFKFB3-67
|
Others
|
Metabolic Disease
|
|
AZ-PFKFB3-67 is potent and selective metabolic kinase PFKFB3 inhibitor, with IC50s of 11, 159 and 1130 nM for PFKFB3, PFKFB2 and PFKFB1 respectively.
|
-
- HY-44154
-
|
PSB-CB5
|
Others
|
Metabolic Disease
|
|
PSB-CB5 is a potent and selective antagonist of GRP18. PSB-CB5 has the potential for the research of metabolic disease and obesity.
|
-
- HY-108680
-
-
- HY-103391
-
|
Qc1
|
Others
|
Metabolic Disease
|
|
Qc1 is a reversible and noncompetitive threonine dehydrogenase (TDH) inhibitor. Qc1 can be used for the research of Metabolic disease.
|
-
- HY-108557
-
-
- HY-101972A
-
-
- HY-W017443
-
-
- HY-147296
-
-
- HY-141668
-
|
BCAT-IN-1
|
Others
|
Metabolic Disease
|
|
BCAT-IN-1 is a potent, selective and orally active inhibitor of BCATm, with a pIC50 of 7.3. BCAT-IN-1 shows 100-fold selectivity for BCATm over BCATc (pIC50=5.4). BCAT-IN-1 can be used for the research of metabolic diseases.
|
-
- HY-146742
-
-
- HY-18541
-
-
- HY-144312
-
-
- HY-151963
-
-
- HY-150067
-
|
CB1R antagonist 1
|
Cannabinoid Receptor
|
Metabolic Disease
|
|
CB1R Allosteric modulator 5, a selective cannabinoid-1 receptor (CB1R) inverse agonist with an IC50 value of 4.2 μM and EC50 value of ＞10 μM. CB1R Allosteric modulator 5 can be used for the research of metabolic and obesity.
|
-
- HY-147049
-
|
PAL-4
|
Others
|
Metabolic Disease
|
|
PAL-4 (compound 4) is a potent, selective and reversible Lysophospholipase-like 1 (LYPLAL1) activator with EC50 value of 0.39 μM and 0.49 μM for mice LYPLAL1 and huamn LYPLAL1, respectively. PAL-4 can be used for researching metabolic disorders.
|
-
- HY-16434
-
|
DGAT1-IN-3
|
Acyltransferase
|
Metabolic Disease
|
|
DGAT1-IN-3 is a potent, selective and orally bioavailable inhibitor of DGAT-1, with IC50s of 38 nM for human DGAT-1 and 120 nM for rat DGAT-1. DGAT1-IN-3 could be used to research of obesity, dyslipidemia, and metabolic syndrome.
|
-
- HY-144313
-
-
- HY-18646
-
-
- HY-101930A
-
|
(Rac)-BMS-816336
|
11β-HSD
|
Metabolic Disease
|
|
(Rac)-BMS-816336 (Compound 6n) is a racemate of BMS-816336. (Rac)-BMS-816336 is a potent inhibitor of human and mouse 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme with IC50s of 10 nM and 68 nM, respectively. (Rac)-BMS-816336 has good metabolic stability.
|
-
- HY-124557
-
-
- HY-151685
-
|
Kdo Azide
|
ADC Linker
|
Others
|
|
Kdo Azide is a click chemistry reagent containing an azide. Kdo Azide is a metabolic labeling reagent.
|
-
- HY-114011
-
-
- HY-123090
-
|
11β-HSD1-IN-12
|
11β-HSD
|
Metabolic Disease
|
|
11β-HSD1-IN-12 is a 11β-HSD1 inhibitor (Example 21 in reference patent). 11β-HSD1 regenerates active glucocorticoids from inactive forms and is important in regulating intracellular glucocorticoid concentration. 11β-HSD1-IN-12 can be used in the research of obesity and metabolic syndrome.
|
-
- HY-148207
-
|
S-Benzylglutathione
|
Amino Acid Derivatives
|
Metabolic Disease
|
|
S-Benzylglutathione is a competitive glutathionase inhibitor. S-Benzylglutathione is converted to the corresponding cysteine derivatives by rat kidney microsomes. S-Benzylglutathione can be used for the research of metabolic breakdown of glutathione by the glutathionase system.
|
-
- HY-148189
-
|
Aldometanib
LXY-05-029
|
AMPK
|
Metabolic Disease
|
|
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis.
|
-
- HY-16946
-
|
CP-610431
|
Acetyl-CoA Carboxylase
|
Metabolic Disease
|
|
CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC50s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome.
|
-
- HY-153531
-
-
- HY-148212
-
-
- HY-D1168
-
|
Oil Red O
|
Fluorescent Dye
|
Metabolic Disease
|
|
Oil Red O is a fat-soluble diazol dye, with a maximum absorption at 518 nm. Oil Red O stains neutral lipids and cholesteryl esters but not biological membranes. Oil Red O can be used for detecting and quantifying hepatic steatosis in mouse liver biopsies. Oil Red O staining efficiently helps to visualize the radical changes that occur in tissues as metabolic disease occurs and progresses.
|
-
- HY-143614
-
|
THR-β agonist 3
|
Others
|
Metabolic Disease
|
|
THR-β agonist 3 is a potent agonist of THR-β. THR-β agonist 3 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021129827A1, compound 6).
|
-
- HY-143613
-
|
THR-β agonist 2
|
Others
|
Metabolic Disease
|
|
THR-β agonist 2 is a potent agonist of THR-β. THR-β agonist 2 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021121210A1, compound 3).
|
-
- HY-133556
-
|
IQZ23
|
AMPK
|
Metabolic Disease
|
|
IQZ23 inhibits adipocyte differentiation via AMPK pathway activation. IQZ23 exerts a high efficacy in decreasing the triglyceride level (EC50=0.033 μM) in 3T3-L1 adipocytes. IQZ23 could be used for the research of obesity and related metabolic disorders.
|
-
- HY-142917
-
|
THR-β agonist 4
|
Others
|
Metabolic Disease
|
|
THR-β agonist 4 is a potent agonist of THR-β. THR-β agonist 4 has the potential for the research of metabolic diseases such as obesity, hyperlipidemia, hypercholesterolemia, diabetes and other conditions such as steatosis and non-alcoholic steatohepatitis (NASH), atherosclerosis and other related conditions and diseases (extracted from patent WO2021143706A1, compound 72).
|
-
- HY-113013
-
|
Hydroxypyruvic acid
β-Hydroxypyruvic acid; 3-Hydroxypyruvic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Hydroxypyruvic acid (β-Hydroxypyruvic acid) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.
|
-
- HY-148208
-
|
S-(p-Nitrobenzyl)glutathione
|
Amino Acid Derivatives
|
Metabolic Disease
|
|
S-(p-Nitrobenzyl)glutathione is a competitive glutathionase inhibitor. S-(p-Nitrobenzyl)glutathione is converted to the corresponding cysteine derivatives by rat kidney microsomes. S-(p-Nitrobenzyl)glutathione can be used for the research of metabolic breakdown of glutathione by the glutathionase system.
|
-
- HY-153476
-
|
GIP/GLP-1 dual receptor agonist-1
|
GCGR
|
Metabolic Disease
|
|
GIP/GLP-1 dual receptor agonist-1 (compound 4) is a GIP/GLP-1 receptor agonist. GIP/GLP-1 dual receptor agonist-1 can be used in the research of metabolic disorders and fatty liver diseases, including nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD).
|
-
- HY-135425
-
|
10,12-Tricosadiynoic acid
|
Acyltransferase
|
Metabolic Disease
|
|
10,12-Tricosadiynoic acid is a highly specific, selective, high affinity and orally active acyl-CoA oxidase-1 (ACOX1) inhibitor. 10,12-Tricosadiynoic acid can treat high fat diet- or obesity-induced metabolic diseases by improving mitochondrial lipid and ROS metabolism.
|
-
- HY-113013A
-
|
Hydroxypyruvic acid lithium hydrate
β-Hydroxypyruvic acid lithium hydrate; 3-Hydroxypyruvic acid lithium hydrate
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Hydroxypyruvic acid lithium hydrate (β-Hydroxypyruvic acid lithium hydrate) is an intermediate in the metabolism of glycine, serine and threonine. Hydroxypyruvic acid lithium hydrate is a substrate for serine-pyruvate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Hydroxypyruvic acid lithium hydrate is involved in the metabolic disorder which is the dimethylglycine dehydrogenase deficiency pathway.
|
-
- HY-136561
-
-
- HY-B1779
-
|
Sucrose
D-(+)-Saccharose
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preference, and diabetes, et al.
|
-
- HY-147361
-
|
LDCA
|
Apoptosis
Lactate Dehydrogenase
|
Cancer
|
|
LDCA is a dual-hit metabolic modulator and inhibits LDH-A enzyme activity to stimulate apoptosis in the malignant population. LDCA can be used for the research of oncogenic progression.
|
-
- HY-N7687
-
|
Caulophyllogenin
|
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
|
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC50 of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation.
|
-
- HY-B0863
-
|
Glyphosate
|
Apoptosis
Autophagy
|
Cancer
|
|
Glyphosate is an herbicidal derivative of the amino acid glycine. Glyphosate targets and blocks a plant metabolic pathway not found in animals, the shikimate pathway, required for the synthesis of aromatic amino acids in plants.
|
-
- HY-152479
-
|
Topoisomerase IIα-IN-7
|
Topoisomerase
|
Cancer
|
|
Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC50 value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability.
|
-
- HY-142940
-
|
RORγt modulator 5
|
ROR
|
Inflammation/Immunology
|
|
RORγt modulator 5 is a RORγt modulator with a Ki value of <100 nM. RORγt modulator 5 has the potential for inflammatory, metabolic, autoimmune and other diseases mediated by RORy study (WO2017132432A1; compound 2).
|
-
- HY-132205
-
|
DS45500853
|
Estrogen Receptor/ERR
|
Metabolic Disease
|
|
DS45500853 is an estrogen-related receptor α (ERRα) agonist. DS45500853 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.80 μM. DS45500853 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM).
|
-
- HY-147246
-
|
Berberine ursodeoxycholate
HTD1801; BUDCA
|
Others
|
Metabolic Disease
|
|
Berberine ursodeoxycholate (HTD1801), an ionic salt of Berberine and Ursodeoxycholic acid, is an orally active and potent hypolipidemic agent. Berberine ursodeoxycholate shows significantly great reduction in liver fat content. Berberine ursodeoxycholate has a broad spectrum of metabolic activity. Berberine ursodeoxycholate can be used for the research of hyperlipidemia, non-alcoholic steatohepatitis (NASH) and diabetes.
|
-
- HY-117516
-
|
SR10067
|
REV-ERB
|
Metabolic Disease
Neurological Disease
|
|
SR10067 is a potent, selective and brain penetrant REV-ERB agonist. SR10067 has high affinity for Rev-Erbβ and Rev-Erbα with IC50 values of 160 nM and 170 nM, respectively. SR10067 can be used for the research of metabolic diseases and neuropsychiatric disorders.
|
-
- HY-143862
-
|
Pparδ agonist 7
|
PPAR
|
Metabolic Disease
|
|
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4).
|
-
- HY-143863
-
|
PPARδ agonist 8
|
PPAR
|
Metabolic Disease
|
|
Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2).
|
-
- HY-50861
-
|
AZD3988
|
Acyltransferase
|
Metabolic Disease
|
|
AZD3988 is an orally active diacylglycerol acyl transferase-1 (DGAT-1) inhibitor. AZD3988 has excellent DGAT-1 (human) potency with an IC50 value of 0. 6 nM. AZD3988 can be used for the research of metabolic diseases such as diabetes, obesity.
|
-
- HY-131445B
-
|
RR-RJW100
|
Others
|
Metabolic Disease
|
|
RR-RJW100, the enantiomer of RJW100, is an nuclear receptor liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1) agonist. RJW100 can be synthesized as two enantiomers, RR-RJW100 and SS-RJW100, with RR-RJW100 shown to be the more potent LRH-1 agonist. RR-RJW100 is involved in the regulation of metabolic homeostasis and is used in studies of diabetes, liver disease and inflammatory bowel disease.
|
-
- HY-145954
-
|
NAT2-IN-1
APA
|
Others
|
Cancer
|
|
NAT2-IN-1 (APA) is an inhibitor of agent metabolic enzyme N-acetyltransferase 2 (NAT2). NAT2-IN-1 can selectively kill slow NAT2 cells.
|
-
- HY-147037
-
|
AMPK activator 7
|
AMPK
|
Metabolic Disease
Cardiovascular Disease
|
|
AMPK activator 7 (compound I-3-24) is a an AMPK activator with the EC50 of 8.8 nM. AMPK activator 7 can be used for the research of diseases involving AMPK, particularly diseases such as type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia and/or hypertension.
|
-
- HY-W000800
-
|
cis,cis-Muconic acid
|
Endogenous Metabolite
|
Others
|
|
cis,cis-Muconic acid, a metabolic intermediate of Klebsiella pneumonia, can be converted to adipic acid and terephthalic acid, which are important monomers of synthetic polymers. cis,cis-Muconic acid is also a biochemical material that can be used for the production of various plastics and polymers and is particularly gaining attention as an adipic acid precursor for the synthesis of nylon-6,6.
|
-
- HY-146731
-
|
PPARγ agonist 1
|
PPAR
|
Metabolic Disease
Cardiovascular Disease
|
|
PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders.
|
-
- HY-103462
-
|
TC-F2
|
FAAH
|
Cancer
Inflammation/Immunology
Metabolic Disease
|
|
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders.
|
-
- HY-146398
-
|
AMPK activator 6
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 6 (Compound GC) reduces lipid content and activates the AMPK pathway in HepG2 and 3T3-L1 cells. AMPK activator 6 significantly suppresses the increase in triglyceride (TG) , total cholesterol (TC), low-density lipoprotein-C (LDL-C), and other biochemical indices in blood serum. AMPK activator 6 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome.
|
-
- HY-146486
-
|
P2Y2R/GPR17 antagonist 1
|
P2Y Receptor
|
Inflammation/Immunology
|
|
P2Y2R/GPR17 antagonist 1 (Compound 14m) is a dual P2Y2R and GPR17 antagonist with IC50 values of 3.17 µM and 1.67 µM against P2Y2R and GPR17, respectively. P2Y2R/GPR17 antagonist 1 shows excellent metabolic stability in human liver microsomes.
|
-
- HY-143201
-
|
DS20362725
|
Estrogen Receptor/ERR
|
Metabolic Disease
|
|
DS20362725 is an estrogen-related receptor α (ERRα) agonist. DS20362725 inhibits the binding between receptor-interacting protein 140 (RIP140) corepressor peptide (10 nM) and GST-ERRα ligand-binding domain (LBD; 1.2 μM) with an IC50 value of 0.6 μM. DS20362725 can be used for the research of metabolic disorders, including type 2 diabetes mellitus (T2DM).
|
-
- HY-150700
-
|
RLX-33
|
ERK
|
Metabolic Disease
|
|
RLX-33 is a potent, selective and blood-brain barrier (BBB) penetrant relaxin family peptide 3 (RXFP3) antagonist, also blocks relaxin-3-induced ERK1/2 phosphorylation, with IC50 values of 2.36 μM for RXFP3, 7.82 and 13.86 μM for ERK1 and ERK2 phosphorylation, respectively. RLX-33 can block the stimulation of food intake induced by the RXFP3-selective agonist R3/I5 in rats. RLX-33 can be used for the research of metabolic syndrome.
|
-
- HY-124113
-
|
4'-Bromo-resveratrol
4′‐BR
|
Sirtuin
Apoptosis
|
Cancer
|
|
4'-Bromo-resveratrol is a potent and dual inhibitor Sirtuin-1 and Sirtuin-3. 4'-Bromo-resveratrol inhibits melanoma cell growth through mitochondrial metabolic reprogramming. 4'-Bromo-resveratrol imparts antiproliferative effects in melanoma cells through a metabolic reprogramming and affecting the cell cycle and apoptosis signaling.
|
-
- HY-147657
-
-
- HY-125990
-
|
SLC13A5-IN-1
|
Sodium Channel
|
Metabolic Disease
Cardiovascular Disease
|
|
SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5.
|
-
- HY-144827
-
|
AM8936
|
Cannabinoid Receptor
|
Neurological Disease
Metabolic Disease
|
|
AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC50s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with Ki of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc.
|
-
- HY-147866
-
|
Antibacterial agent 110
|
Bacterial
DNA/RNA Synthesis
ROS Kinase
|
Infection
|
|
Antibacterial agent 110 (Compound 4e) is a potent antibacterial agent with a MIC value of 1 μg/mL against P. aeruginosa. Antibacterial agent 110 possesses favorable antibiofilm activity and can destroy cell membranes. Antibacterial agent 110 causes metabolic arrest and intracellular oxidative stress, and obstructs DNA replication.
|
-
- HY-146120
-
|
Antitubercular agent-25
|
Bacterial
|
Infection
|
|
Antitubercular agent-25 (Compound 28) is an anti-tubercular agent with an extracellular IC50 of 0.42 μM and an intracellular IC50 of 0.20 μM against M. tuberculosis H37Rv. Antitubercular agent-25 exhibits good metabolic stability.
|
-
- HY-D0016
-
|
5-Cyano-2,3-di-(p-tolyl)tetrazolium chloride
CTC
|
Fluorescent Dye
|
Others
|
|
5-Cyano-2,3-di-(p-tolyl)tetrazolium chloride (CTC) is a redox-sensitive red fluorescent dye. 5-Cyano-2,3-di-(p-tolyl)tetrazolium chloride can be used for detecting metabolic activity in microorganisms. The emission maximum of 5-Cyano-2,3-di-(p-tolyl)tetrazolium chloride is 602 nm.
|
-
- HY-D1341
-
|
Coumberone
|
Fluorescent Dye
|
Cancer
|
|
Coumberone is a metabolic fluorogenic probe, and isoform-selective substrate for all AKR1C isoforms. Coumberone can be reduced by all four members of the AKR1C family to its fluorescent alcohol coumberol. Coumberone can be used for the research of AKR1C.
|
-
- HY-147086
-
|
CAY10789
|
Leukotriene Receptor
G protein-coupled Bile Acid Receptor 1
TNF Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
CAY10789 (compound 6) is a potent CysLT1R (cysteinyl leukotriene receptor 1) antagonist (IC50=2.80 μM) and GPBAR1 (G-protein-coupled bile acid receptor 1) agonist (EC50=3 μM). CAY10789 significantly reduces the adhesion of U937 cells to HAEC, reduces the expression of TNF-α. CAY10789 shows very promising metabolic stability and excellent pharmacokinetics. CAY10789 can be used for the research of colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases.
|
-
- HY-115981
-
|
NS5A-IN-2
|
HCV Protease
|
Infection
|
|
NS5A-IN-2 (Compound 33) is a potent inhibitor of NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability.
|
-
- HY-147063
-
|
N-Acetyl-α-D-glucosamine 1-phosphate disodium
|
Endogenous Metabolite
|
Others
|
|
N-acetyl-α-d-glucosamine 1-phosphate disodium (GlcNAc-1-P), an anomeric sugar phosphate, is a key intermediate in the biosynthesis of N-linked glycoproteins. N-acetyl-α-d-glucosamine 1-phosphate disodium is a metabolic precursor of the bacterial cell-wall components teichoic acid and mureine.
|
-
- HY-F0003
-
|
NADPH tetrasodium salt
|
Ferroptosis
Endogenous Metabolite
|
Cancer
|
|
NADPH tetrasodium salt functions as an important cofactor in a variety of metabolic and biosynthetic pathways. NADPH tetrasodium salt plays a vital role in the biosynthesis of agents, chiral alcohols, fatty acids and biopolymers, while also being required for lipid biosynthesis, biomass formation, and cell replication. The demand for NADPH tetrasodium salt is particularly high in proliferating cancer cells, where it acts as a cofactor for the synthesis of nucleotides, proteins, and fatty acids. NADPH tetrasodium salt is also essential for the neutralization of the dangerously high levels of reactive oxygen species (ROS) generated by increased metabolic activity. NADPH tetrasodium salt is an endogenous inhibitor of ferroptosis.
|
-
- HY-150578
-
-
- HY-146111
-
|
IRAK4-IN-13
|
IRAK
|
Cancer
|
|
IRAK4-IN-13 (compound 21) is a potent and selective IRAK4 inhibitor with an IC50 of 0.6 nM. IRAK4-IN-13 shows high metabolic clearance with human liver microsomes (HLM) intrinsic clearance is 96 µL/min/mg.
|
-
- HY-13012
-
|
RepSox
E-616452; SJN 2511
|
TGF-β Receptor
|
Metabolic Disease
|
|
RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes.
|
-
- HY-B0543
-
-
- HY-Y0445A
-
|
Sodium dichloroacetate
|
PDHK
Reactive Oxygen Species
NKCC
Apoptosis
|
Cancer
|
|
Sodium dichloroacetate is a metabolic regulator in cancer cells' mitochondria with anticancer activity. Sodium dichloroacetate inhibits PDHK, resulting in decreased lactic acid in the tumor microenvironment. Sodium dichloroacetate increases reactive oxygen species (ROS) generation and promotes cancer cell apoptosis. Sodium dichloroacetate also works as NKCC inhibitor.
|
-
- HY-151616
-
|
sEH inhibitor-10
|
Epoxide Hydrolase
|
Metabolic Disease
Inflammation/Immunology
Cardiovascular Disease
|
|
sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases.
|
-
- HY-143406
-
|
Antifungal agent 25
|
Fungal
|
Infection
|
|
Antifungal agent 25 is a potent broad-spectrum antifungal agent. Antifungal agent 25 shows antifungal effect against Candida albicans and fluconazole-resistant strain of Candida albicans. Antifungal agent 25 stable metabolic property in vivo.
|
-
- HY-B0399
-
|
L-Carnitine
(R)-Carnitine; Levocarnitine
|
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
L-Carnitine ((R)-Carnitine), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine is an antioxidant. L-Carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism.
|
-
- HY-148210
-
|
AMPK activator 9
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 9 (ZM-6) is a potent AMPK (α2β1γ1) activator with an EC50 value of 1.1 µM. AMPK activator 9 has the potential for the research of type 2 diabetes.
|
-
- HY-147627
-
-
- HY-U00358
-
-
- HY-134433
-
|
GDP-L-fucose
|
Endogenous Metabolite
|
Metabolic Disease
|
GDP-L-fucose is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides, providing the fucose moiety for the oligosaccharides.The formation of GDP-L-fucose occurs through two pathways, the major ab initio metabolic pathway and the minor remedial metabolic pathway.
|
-
- HY-123033A
-
|
Nicotinamide riboside chloride
|
Sirtuin
Endogenous Metabolite
|
Metabolic Disease
Neurological Disease
Cancer
|
|
Nicotinamide riboside Chloride, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease.
|
-
- HY-123033
-
|
Nicotinamide riboside
|
Sirtuin
Endogenous Metabolite
|
Metabolic Disease
Neurological Disease
Cancer
|
|
Nicotinamide riboside, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease.
|
-
- HY-124304
-
|
Pinokalant
LOE-908
|
TRP Channel
SARS-CoV
|
Neurological Disease
|
|
Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity.
|
-
- HY-113107
-
-
- HY-P1064
-
|
Apelin-36(human)
|
HIV
|
Infection
Metabolic Disease
Cardiovascular Disease
|
|
Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
|
-
- HY-107460
-
|
LDN-211904 oxalate
|
Ephrin Receptor
|
Cancer
|
|
LDN-211904 oxalate (compound 32) is a potent and selective EphB3 inhibitor with an IC50 of 0.079 µM. LDN-211904 oxalate shows good metabolic stability in mouse liver microsomes. LDN-211904 oxalate with cetuximab could be effective in inhibiting STAT3-activated CSC stemness and cetuximab resistance in CRC.
|
-
- HY-123033B
-
|
Nicotinamide riboside tartrate
|
Sirtuin
Endogenous Metabolite
|
Metabolic Disease
Neurological Disease
Cancer
|
|
Nicotinamide riboside tartrate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease.
|
-
- HY-123033C
-
|
Nicotinamide riboside malate
|
Sirtuin
Endogenous Metabolite
|
Metabolic Disease
Neurological Disease
Cancer
|
|
Nicotinamide riboside malate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities. Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease.
|
-
- HY-P1064A
-
|
Apelin-36(human) TFA
|
HIV
|
Infection
Metabolic Disease
Cardiovascular Disease
|
|
Apelin-36(human) TFA is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC550=8.61). Apelin-36(human) TFA has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
|
-
- HY-147108
-
-
- HY-134433A
-
|
GDP-L-fucose disodium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
GDP-L-fucose disodium is a nucleotide sugar that is a key substrate for the biosynthesis of fucose oligosaccharides. GDP-L-fucose disodium provides the fucose moiety for the oligosaccharides. The formation of GDP-L-fucose disodium occurs through two pathways, the major de novo metabolic pathway and the minor remedial metabolic pathway.
|
-
- HY-P1944A
-
|
Apelin-13 TFA
|
Apelin Receptor (APJ)
|
Metabolic Disease
Cardiovascular Disease
|
|
Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome.
|
-
- HY-16986
-
|
EPZ011989
|
Histone Methyltransferase
|
Cancer
|
|
EPZ011989 is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ011989 has inhibitory inhibition for EZH2 with a Ki value of <3 nM. EPZ011989 shows robust methyl mark inhibition and anti-tumor activity. EPZ011989 can be used for the research of various cancers.
|
-
- HY-P4040
-
-
- HY-142441
-
|
THR-β agonist 1
|
Others
|
Endocrinology
|
|
THRβ Agonist 1 is a potent and selective agonist of THRβ. Thyroid hormone receptor mediates the physiological activity of thyroid hormones which plays a key role in normal growth and development of the body and in maintaining metabolic balance. THRβ Agonist 1 has the potential for the research of thyroid hormone receptor-related diseases (extracted from patent WO2021104288A1, compound 2).
|
-
- HY-132924
-
-
- HY-16986A
-
|
EPZ011989 trifluoroacetate
EPZ-011989 trifluoroacetate
|
Histone Methyltransferase
|
Cancer
|
|
EPZ-011989 trifluoroacetate is a potent and orally active Zeste Homolog 2 (EZH2) inhibitor with metabolic stability. EPZ-011989 trifluoroacetate has inhibitory inhibition for EZH2 with a Ki value of <3 nM. EPZ-011989 trifluoroacetate shows robust methyl mark inhibition and anti-tumor activity. EPZ-011989 trifluoroacetate can be used for the research of various cancers.
|
-
- HY-145624
-
-
- HY-14280
-
|
Entacapone
|
COMT
|
Neurological Disease
|
|
Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders.
|
-
- HY-144286
-
|
CXCR4 antagonist 3
|
CXCR
|
Infection
|
|
CXCR4 antagonist 3 (compound 12a) is a potent antagonist of CXCR4 with an IC50 of 11 nM. CXCR4 antagonist 3 is a congener of TIQ15. CXCR4 antagonist 3 demonstrates the best overall properties including CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. CXCR4 antagonist 3 has the potential for the research of human immunodeficiency virus.
|
-
- HY-B0051
-
-
- HY-153530
-
|
LI-2242
|
Others
|
Metabolic Disease
Neurological Disease
|
LI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders.
|
-
- HY-132830
-
-
- HY-151340
-
|
Antitubercular agent-32
|
Bacterial
|
Infection
|
|
Antitubercular agent-32 is a derivate of Benzothiazinone (HY-13579A), inhibits M. tuberculosis, and shows improved metabolic stability and enhanced water solubility. Antitubercular agent-32 exerts antitubercular effect by targeting decaprenylphosphoryl-β-D-ribose 2’-oxidase (DprE1, IC50=3.9 μM).
|
-
- HY-B2176
-
|
ATP
Adenosine 5'-triphosphate
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation.
|
-
- HY-P1944
-
|
Apelin-13
|
Apelin Receptor (APJ)
|
Metabolic Disease
Cardiovascular Disease
|
|
Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome.
|
-
- HY-148978
-
-
- HY-148977
-
-
- HY-W010735
-
|
ATP disodium salt hydrate
Adenosine 5'-triphosphate disodium salt hydrate
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
ATP disodium salt hydrate (Adenosine 5'-triphosphatedisodium salt hydrate) is a central component of energy storage and metabolism in vivo, provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium salt hydrate is an important endogenous signaling molecule in immunity and inflammation.
|
-
- HY-115982
-
|
NS5A-IN-3
|
HCV Protease
|
Infection
|
|
NS5A-IN-3 (Compound 15) is a potent inhibitor of NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b.
|
-
- HY-121524
-
|
DJ101
|
Microtubule/Tubulin
|
Cancer
|
|
DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research.
|
-
- HY-14280A
-
|
Entacapone sodium salt
|
COMT
|
Neurological Disease
|
|
Entacapone sodium salt is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone sodium salt inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone sodium salt is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone sodium salt can be used for the research of Parkinson's disease. Entacapone sodium salt serves as as a inhibit of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders.
|
-
- HY-115831
-
|
SAR247799
S1P1 agonist 3
|
LPL Receptor
|
Cardiovascular Disease
|
|
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC50s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome.
|
-
- HY-B2176D
-
|
ATP ditromethamine
Adenosine 5'-triphosphate ditromethamine
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
ATP ditromethamine (Adenosine 5'-triphosphate ditromethamine) is a central component of energy storage and metabolism in vivo. ATP ditromethamine provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP ditromethamine is an important endogenous signaling molecule in immunity and inflammation.
|
-
- HY-117178
-
-
- HY-W018004
-
-
- HY-113284
-
|
Succinyladenosine
N6-Succinyl adenosine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Succinyladenosine, the metabolic product of dephosphorylation of intracellular adenylosuccinic acid (S-AMP) by cytosolic 5-nucleotidase, is a biochemical marker of adenylosuccinase (ASL) deficiency.
|
-
- HY-145605
-
|
Vutiglabridin
HSG4112
|
Others
|
Metabolic Disease
|
|
Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability.
|
-
- HY-N7439
-
|
Mogroside VI B
|
PGC-1α
|
Metabolic Disease
|
|
Mogroside VI B, a cucurbitane glucoside, separated from the crude extract of Siraitia grosvenorii. Mogroside VI B shows effect on activating PGC-1α transcription.
|
-
- HY-W012499
-
-
- HY-N6724
-
|
Altertoxin I
Dihydroalterperylenol
|
Others
|
Metabolic Disease
|
|
Altertoxin I (Dihydroalterperylenol) is a quinone-type mycotoxin produced by Alternaria alternata fungi, which is mutagenic and cytotoxic, and can weakly disrupts metabolic communication.
|
-
- HY-B0345A
-
|
ATP disodium salt
Adenosine 5'-triphosphate disodium salt; Disodium adenosine triphosphate
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
ATP disodium salt (Adenosine 5'-triphosphate disodium salt) is a central component of energy storage and metabolism in vivo, provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium salt is an important endogenous signaling molecule in immunity and inflammation.
|
-
- HY-113288
-
|
Campestanol
|
Others
|
Metabolic Disease
|
|
Campestanol is a phytosterol that can be found in plant food. Campestanol lowers serum cholesterol and low-density lipoprotein. Campestanol can be used for the research of metabolic disorders.
|
-
- HY-P2542
-
-
- HY-B2176C
-
|
ATP dipotassium
Adenosine 5'-triphosphate dipotassium
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
ATP dipotassium (Adenosine 5'-triphosphate dipotassium) is a central component of energy storage and metabolism in vivo. ATP dipotassium provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP dipotassium is an important endogenous signaling molecule in immunity and inflammation.
|
-
- HY-148104
-
-
- HY-113344
-
-
- HY-114392
-
|
Gly-β-MCA
|
FXR
Autophagy
|
Metabolic Disease
|
|
Gly-β-MCA, a bile acid, is a potent, sable, intestine-selective and oral bioactive farnesoid X receptor (FXR) inhibitor that may be a candidate for the treatment of metabolic disorders.
|
-
- HY-P99755
-
-
- HY-W011956
-
-
- HY-145781
-
|
β-L-Fucopyranosyl phosphate
|
Others
|
Metabolic Disease
|
|
β-L-Fucopyranosyl phosphate can be used for the research of carbohydrate metabolism. Glycosyl phosphates play crucial roles in carbohydrate metabolism as metabolic regulators or ubiquitous intermediates for glycoconjugate biosynthesis.
|
-
- HY-113230
-
-
- HY-113230B
-
-
- HY-101455
-
|
CDN1163
|
Calcium Channel
|
Metabolic Disease
|
|
CDN1163 is an allosteric sarco/endoplasmic reticulum Ca 2+-ATPase (SERCA) activator that improves Ca 2+ homeostasis. CDN1163 attenuates diabetes and metabolic disorders.
|
-
- HY-B2176A
-
|
ATP disodium trihydrate
Adenosine-5'-triphosphate disodium trihydrate
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
ATP disodium trihydrate (Adenosine 5'-triphosphate disodium trihydrate) is a central component of energy storage and metabolism in vivo. ATP disodium trihydrate provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium trihydrate is an important endogenous signaling molecule in immunity and inflammation.
|
-
- HY-W017443S1
-
-
- HY-107850
-
-
- HY-N5134
-
|
5'-Guanylic acid
5'-GMP; 5'-guanosine monophosphate
|
Endogenous Metabolite
|
Metabolic Disease
|
|
5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
|
-
- HY-134424
-
|
Propionyl coenzyme A lithium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Propionyl coenzyme A lithium, a coenzyme A derivative of propionic acid, is an important metabolic intermediate formed by the thioester bond between coenzyme A and propionic acid. The breakdown and production of Propionyl coenzyme A lithim is important for the metabolism of organisms.
|
-
- HY-137178
-
-
- HY-D0195
-
-
- HY-W018004S
-
|
L-Homocitrulline-d3
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Homocitrulline-d3 is the deuterium labeled L-Homocitrulline. L-Homocitrulline is metabolized to homoarginine through homoargininosuccinate via the urea cycle pathway and its metabolic abnormality could lead to Lysinuric Protein Intolerance (LPI).
|
-
- HY-B2176S1
-
|
ATP-13C10,15N5 disodium
Adenosine 5'-triphosphate-13C10,15N5 (disodium)
|
Endogenous Metabolite
|
Metabolic Disease
Inflammation/Immunology
|
|
ATP- 13C10, 15N5 (disodium) is a 13C-labeled and 15N-labeled ATP (HY-B2176). ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation[1][2][3][4].
|
-
- HY-146617
-
|
GLS1 Inhibitor-4
|
Glutaminase
Apoptosis
|
Cancer
|
|
GLS1 Inhibitor-4 (compound 41e) is a potent GLS1 inhibitor with an IC50 of 11.86 nM. GLS1 Inhibitor-4 shows antiproliferative activity, good metabolic stability, robust GLS1 binding affinity. GLS1 Inhibitor-4 blocks the glutamine metabolism and induce the production of ROS. GLS1 Inhibitor-4 induces apoptosis and shows antitumor activity.
|
-
- HY-113131
-
|
Dihydroxyacetone phosphate
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. It is a biochemical compound involved in many metabolic pathways, including the Calvin cycle in plants and glycolysis. Dihydroxyacetone phosphate is found to be associated with transaldolase deficiency, which is an inborn error of metabolism.
|
-
- HY-118297
-
-
- HY-153525
-
-
- HY-N11395
-
|
Latrodectus Tredecimguttatus Venom
Mediterranean Black Widow Venom
|
Others
|
Metabolic Disease
|
|
Latrodectus Tredecimguttatus Venom (Mediterranean Black Widow Venom) is a venom that can be obtained from Mediterranean black widow spider. Latrodectus Tredecimguttatus Venom is rich in metabolic enzymes and shows activities of multiple hydrolases including protease, DNAase, and phosphatase.
|
-
- HY-113131A
-
|
Dihydroxyacetone phosphate hemimagnesium hydrate
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Dihydroxyacetone phosphate hemimagnesium hydrate is an important intermediate in lipid biosynthesis and in glycolysis. It is a biochemical compound involved in many metabolic pathways, including the Calvin cycle in plants and glycolysis. Dihydroxyacetone phosphate hemimagnesium hydrate is found to be associated with transaldolase deficiency, which is an inborn error of metabolism.
|
-
- HY-112340
-
|
TM38837
|
Cannabinoid Receptor
|
Metabolic Disease
|
|
TM38837 is a peripheral selective cannabinoid receptor type 1 (CB1) receptor antagonist. TM38837 shows limited penetrance to the brain in order to minimize or prevent CNS adverse reactions, and preserves potential antiobesity effects. TM38837 reduces propensity for psychiatric side effects.
|
-
- HY-N0401B
-
-
- HY-101190
-
-
- HY-110092
-
|
PSB-1114 tetrasodium
|
P2Y Receptor
|
Metabolic Disease
|
|
PSB-1114 tetrasodium is a potent, enzymatically stable, and subtype-selective P2Y2 receptor agonist with an EC50 of 134 nM. PSB-1114 tetrasodium displays >50-fold selectivity versus the P2Y4 (EC50 of 9.3 μM) and P2Y6 (EC50 of 7.0 μM) receptors.
|
-
- HY-W017443S3
-
-
- HY-W017443S4
-
-
- HY-101748
-
-
- HY-W010382S
-
-
- HY-A0213B
-
|
Tiludronate disodium hemihydrate
Tiludronic acid disodium hemihydrate
|
Proton Pump
|
Metabolic Disease
|
|
Tiludronate (Tiludronic Acid) disodium hemihydrate, an orally active bisphosphonate, can act an osteoregulator. Tiludronate disodium hemihydrate is used for the research of the metabolic bone disorders. Tiludronate disodium hemihydrate is a potent inhibitor of the osteoclast vacuolar H +-ATPase. Antiresorptive and anti-inflammatory properties.
|
-
- HY-W017443S
-
-
- HY-124156A
-
|
KY-02327 acetate
|
Wnt
|
Metabolic Disease
|
|
KY-02327 acetate, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 acetate shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation.
|
-
- HY-14414
-
|
GSK4112
SR6452
|
Apoptosis
|
Metabolic Disease
|
|
GSK4112 (SR6452) is a Rev-erbα agonist with an EC50 value of 0.4 μM. GSK4112 can be used as a chemical tool to probe the function of Rev-erbα in transcriptional repression, regulation of circadian biology, and metabolic pathways.
|
-
- HY-124156
-
|
KY-02327
|
Wnt
|
Metabolic Disease
|
|
KY-02327, a metabolically stabilized KY-02061 analog, is a potent Dishevelled (Dvl)-CXXC5 interaction inhibitor. KY-02327 shows an activating effect on the Wnt/β-catenin pathway, resulting in promotion of osteoblast differentiation.
|
-
- HY-148691
-
-
- HY-128790S1
-
|
4-Methoxyestrone-13C6
|
Endogenous Metabolite
|
Metabolic Disease
|
|
4-Methoxyestrone- 13C6 is a 13C-labeled 5'-Guanylic acid. 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and
|
-
- HY-W082785A
-
-
- HY-121835
-
|
GLP-1R agonist 2
|
GCGR
|
Metabolic Disease
|
|
GLP-1R agonist 2 (compound 2) is a potent GLP-1R agonist. GLP-1R agonist 2 has the potential for the research of metabolic diseases like Type2 Diabetes and Obesity.
|
-
- HY-113377A
-
|
L-Glyceric acid sodium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Glyceric acid sodium is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid sodium can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid sodium excretion to distinguish PH1 from PH2.
|
-
- HY-148247
-
|
BI-2081
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
BI-2081 is a GPR40 (FFAR1) partial agonist (EC50: 4 nM). BI-2081 induces glucose depending insulin secretion and reduces the plasma glucose concentration. BI-2081 can be used in the research of metabolic diseases, in particular diabetes type 2.
|
-
- HY-113377
-
|
L-Glyceric acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Glyceric acid is a mainly urinary metabolite accumulating in rare inherited metabolic disease L-glyceric aciduria. L-Glyceric acid can be used to diagnose primary hyperoxaluria type 2 (PH2). L-Glyceric acid excretion to distinguish PH1 from PH2.
|
-
- HY-19528
-
|
SAH
SAH (S-Adenosylhomocysteine)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM.
|
-
- HY-W017443S2
-
-
- HY-N0390
-
-
- HY-B1779S3
-
|
Sucrose-d14
D-(+)-Saccharose-d14
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
Sucrose-d14 is the deuterium labeled Sucrose. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose can be applied in some animal models, including metabolic disease, obesity, diet on preferen
|
-
- HY-N0288
-
-
- HY-138944
-
-
- HY-14393
-
|
Emodin
Frangula emodin
|
SARS-CoV
Casein Kinase
Autophagy
11β-HSD
|
Cancer
|
|
Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice.
|
-
- HY-112948
-
|
2-Methylbutyrylcarnitine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
2-Methylbutyrylcarnitine is a fatty acid metabolite. 2-Methylbutyrylcarnitine is found mainly in the blood and urine of humans and animals and is produced through the pyruvate carboxylation pathway. 2-Methylbutyrylcarnitine exhibits high level in the plasma of subjects with steatohepatitis (NASH) and can be used as an indicator for the diagnosis of metabolic diseases.
|
-
- HY-P2624
-
|
st-Ht31
|
PAK
|
Metabolic Disease
|
|
st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 induces robust cholesterol/phospholipid efflux. st-Ht31 completely reverses foam cell formation and restores the metabolic health of macrophage.
|
-
- HY-113054
-
-
- HY-152473
-
|
Topoisomerase IIα-IN-6
|
Topoisomerase
|
Cancer
|
|
Topoisomerase IIα-IN-6 (Compound 47d) is an inhibitor of DNA topoisomerase IIα/β. Topoisomerase IIα-IN-6 inhibits human topoisomerase IIα and human topoisomerase IIβ with IC50 values of 0.67 µM and 0.55 µM, respectively. Topoisomerase IIα-IN-6 has stable metabolism.
|
-
- HY-N0390S2
-
|
L-Glutamine-d5
L-Glutamic acid 5-amide-d5
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine-d5 is the deuterium labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-Y1314
-
|
Dimethyl sulfone
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Dimethyl sulfone (Methyl Sulfonyl Methane) is a metabolic product of endogenous methanethiol metabolism and intestinal bacterial metabolism. Dimethyl sulfone inhibits choriocapillary endothelial (CCE) cell proliferation, also has many biological effects, including antiinflammatory, antioxidant, and local anesthetic effects that could be neuroprotective.
|
-
- HY-107901
-
|
Pparδ agonist 1
|
PPAR
|
Metabolic Disease
Cardiovascular Disease
|
|
Pparδ agonist 1 is a PPAR-δ agonist, with an EC50 of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.
|
-
- HY-U00271
-
-
- HY-B0389S4
-
|
D-Glucose-d1-2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose-d-22 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-B0389S7
-
|
D-Glucose-d1-3
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose-d-33 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-N0390S
-
|
L-Glutamine-15N
L-Glutamic acid 5-amide-15N
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine- 15N is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-B0389S5
-
|
D-Glucose-d2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose-d22 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-B0389S10
-
|
D-Glucose-13C
Glucose-13C; D-(+)-Glucose-13C; Dextrose-13C
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-B0389S6
-
|
D-Glucose-d7
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose-d77 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-B0389S8
-
|
D-Glucose-d1-4
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose-d-44 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-P4554
-
|
H-Phe-Arg-OH
|
Endogenous Metabolite
|
Metabolic Disease
|
|
H-Phe-Arg-OH is a dipeptide containing phenylalanine and arginine. H-Phe-Arg-OH can be separated from Bradykinin (HY-P0206) through Angiotensin-converting enzyme (ACE, HY-P2983). H-Phe-Arg-OH can be used for metabolic research.
|
-
- HY-B0389S3
-
|
D-Glucose-d1-1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose-d-11 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-N0390S1
-
|
L-Glutamine-13C5
L-Glutamic acid 5-amide-13C5
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine- 13C5 is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-B0389S14
-
|
D-Glucose-13C2
Glucose-13C2; D-(+)-Glucose-13C2; Dextrose-13C2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C2 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-114196
-
|
Aclimostat
ZGN-1061
|
Others
|
Metabolic Disease
|
|
Aclimostat (ZGN-1061) is a potent inhibitor of the MetAP2 enzyme and displays favorable efficacy and safety in preclinical studies. ZGN-1061 produced similar efficacy as beloranib for weight loss, improvements in metabolic parameters in a mouse model of obesity and insulin resistance, and concordant changes in gene transcription in HepG2 cells.
|
-
- HY-N0390S5
-
|
L-Glutamine-1-13C
L-Glutamic acid 5-amide-1-13C
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine-1- 13C is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-B0389S2
-
|
D-Glucose-d12-1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose-d12-12 is the deuterium labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-P4550
-
|
H-Hyp-Gly-OH
|
Endogenous Metabolite
|
Metabolic Disease
|
|
H-Hyp-Gly-OH is a dipeptide containing hydroxyproline and glycine. H-Hyp-Gly-OH promotes the growth of mouse primary fibroblasts on collagen gel. H-Hyp-Gly-OH has potential applications in improving skin by ingesting hydrolyzed collagen. H-Hyp-Gly-OH can be used for metabolic research.
|
-
- HY-N0390S4
-
|
L-Glutamine-5-13C
L-Glutamic acid 5-amide-5-13C
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine-5- 13C is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-N0390S11
-
|
L-Glutamine-2-13C
L-Glutamic acid 5-amide-2-13C
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine-2- 13C is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-N0390S8
-
|
L-Glutamine-15N2
L-Glutamic acid 5-amide-15N2
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine- 15N2 is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-W012241
-
-
- HY-N0680
-
-
- HY-B2176B
-
|
ATP dimagnesium
Adenosine 5'-triphosphate dimagnesium
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
ATP (Adenosine 5'-triphosphate) dimagnesium is a central component of energy storage and metabolism in vivo. ATP dimagnesium provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP dimagnesium is an important endogenous signaling molecule in immunity and inflammation.
|
-
- HY-B0389S16
-
|
D-Glucose-13C-4
Glucose-13C-4; D-(+)-Glucose-13C-4; Dextrose-13C-4
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C-4 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-B0389S13
-
|
D-Glucose-13C-3
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C-3 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-N0390S10
-
|
L-Glutamine-1,2-13C2
L-Glutamic acid 5-amide-1,2-13C2
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine-1,2- 13C2 is the 13C-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-151500
-
|
JBSNF-000028 free base
|
Others
|
Metabolic Disease
|
|
JBSNF-000028 is an orally active nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 0.033 µM, 0.19 µM and 0.21 µM against human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT), respectively. JBSNF-000028 can be used for the research of metabolic disorders.
|
-
- HY-B0389S17
-
|
D-Glucose-13C-5
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C-5 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-B0389S18
-
|
D-Glucose-13C3-1
Glucose-13C3-1; D-(+)-Glucose-13C3-1; Dextrose-13C3-1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C3-1 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-19528S
-
|
SAH-d4
SAH (S-Adenosylhomocysteine)-d4
|
Endogenous Metabolite
|
Metabolic Disease
|
|
SAH-d4 is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].
|
-
- HY-N0390S9
-
|
L-Glutamine-15N-1
L-Glutamic acid 5-amide-15N-1
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine- 15N-1 is the 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-B0389S11
-
|
D-Glucose-13C-1
Glucose-13C-1; D-(+)-Glucose-13C-1; Dextrose-13C-1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C-1 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-107124
-
|
BMS-770767
|
11β-HSD
|
Metabolic Disease
|
|
BMS-770767 is an 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor in type 2 diabetes. 11β-HSD1 is an important enzyme that is widely expressed in liver, adipose tissue and other tissues and plays an important role in metabolic diseases such as diabetes and obesity.
|
-
- HY-B0389S15
-
|
D-Glucose-13C2-4
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C2-4 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-B0389S12
-
|
D-Glucose-13C-2
Glucose-13C-2; D-(+)-Glucose-13C-2; Dextrose-13C-2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C-2 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-B0389S9
-
|
D-Glucose-13C3-2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C3-2 is the 13C labeled D-Glucose. D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response[1].
|
-
- HY-151500B
-
|
JBSNF-000028 hydrochloride
|
Others
|
Metabolic Disease
|
|
JBSNF-000028 hydrochloride is an orally active nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 0.033 μM, 0.19 μM and 0.21 μM against human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT), respectively. JBSNF-000028 hydrochloride can be used for the research of metabolic disorders.
|
-
- HY-139077
-
-
- HY-N10216
-
|
Cynodontin
|
Others
|
Infection
|
|
Cynodontin is a metabolic product of Helminthosporium cynodontis Marignoni and Helminthosporium euchlaenae Zimmermann.
|
-
- HY-Y0418
-
|
Dulcite
Dulcitol; Melampyrit; NSC 1944
|
Endogenous Metabolite
|
Others
|
|
Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galactose.
|
-
- HY-N0130
-
-
- HY-14363
-
|
TUG-424
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC50 of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity.
|
-
- HY-P2501
-
|
Amylin (8-37), human
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus.
|
-
- HY-N0390S6
-
|
L-Glutamine-13C5,15N2
L-Glutamic acid 5-amide-13C5,15N2
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine- 13C5, 15N2 is the 13C- and 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-19528S1
-
|
SAH-13C5
SAH (S-Adenosylhomocysteine)-13C5
|
Endogenous Metabolite
|
Metabolic Disease
|
|
SAH- 13C5 is the 13C-labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[1]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM[2].
|
-
- HY-N4170
-
|
Chebulic acid
|
Others
|
Metabolic Disease
|
|
Chebulic acid, a phenolcarboxylic acid compound isolated from Terminalia chebula, has potent anti-oxidant activity,
which breaks the cross-links of proteins induced by advanced glycation end-products (AGEs) and inhibits the formation of AGEs. Chebulic acid is effective in controlling elevated metabolic parameters, oxidative stress and renal damage, supporting its beneficial effect in diabetic nephropathy.
|
-
- HY-151500A
-
|
JBSNF-000028 TFA
|
Others
|
Metabolic Disease
|
|
JBSNF-000028 TFA is an orally active nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 0.033 μM, 0.19 μM and 0.21 μM against human NNMT (hNNMT), monkey NNMT (mkNNMT), and mouse NNMT (mNNMT), respectively. JBSNF-000028 TFA can be used for the research of metabolic disorders.
|
-
- HY-U00397
-
-
- HY-14268A
-
-
- HY-14268
-
-
- HY-B1274
-
-
- HY-N2357
-
-
- HY-P4815
-
-
- HY-19528S2
-
|
SAH-13C10
|
Endogenous Metabolite
|
Metabolic Disease
|
|
SAH- 13C10 is the 13C labeled SAH[1]. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine[2]. SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM[3].
|
-
- HY-B2246
-
|
L-Carnitine hydrochloride
(R)-Carnitine hydrochloride; Levocarnitine hydrochloride
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Carnitine hydrochloride ((R)-Carnitine hydrochloride), a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine hydrochloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine hydrochloride is an antioxidant. L-Carnitine hydrochloride can ameliorate metabolic imbalances in many inborn errors of metabolism.
|
-
- HY-N0390S7
-
|
L-Glutamine-15N2,d5
L-Glutamic acid 5-amide-15N2,d5
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine- 15N2,d5 is the deuterium and 15N-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-145249
-
|
ATP-PEG8-Biotin
|
PROTAC Linkers
|
Inflammation/Immunology
|
|
ATP-PEG8-Biotin is a PEG-based linker that incorporates ATP. ATP is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation.
|
-
- HY-B0389
-
|
D-Glucose
Glucose; D-(+)-Glucose; Dextrose; β-D-Glucose anhydrous
|
Endogenous Metabolite
Bacterial
|
Metabolic Disease
Cancer
|
|
D-Glucose (Glucose), a monosaccharide, is an important carbohydrate in biology. D-Glucose is a carbohydrate sweetener and critical components of the general metabolism, and serve as critical signaling molecules in relation to both cellular metabolic status and biotic and abiotic stress response. D-Glucose induces secretion of cell migrasome.
|
-
- HY-115727
-
-
- HY-125120
-
|
Kansuiphorin C
|
Others
|
Others
|
|
Kansuiphorin C ameliorates malignant ascites by modulating gut microbiota and related metabolic functions.
|
-
- HY-116003
-
|
12,13-DiHOME
|
Endogenous Metabolite
|
Metabolic Disease
|
|
12,13-DiHOME is a stimulator of Brown adipose tissue (BAT), as well as a thermogenic lipokine that activates BAT in response to cold. (±)12,13-DiHOME activates BAT fuel uptake and enhances cold tolerance, via promoting the translocation of the FA transporters FATP1 and CD36 to the cell membrane. (±)12,13-DiHOME can be used for research of metabolic disorders.
|
-
- HY-113596
-
|
Acetyl Coenzyme A trisodium
Acetyl-CoA trisodium
|
Endogenous Metabolite
Autophagy
|
Metabolic Disease
|
|
Acetyl-coenzyme A (Acetyl-CoA) trisodium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trisodium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trisodium is also a key precursor of lipid synthesis.
|
-
- HY-151173
-
-
- HY-N0667
-
-
- HY-109167
-
-
- HY-112808
-
|
KAN0438757
|
Autophagy
|
Cancer
|
|
KAN0438757 is a potent and selective inhibitor of the metabolic kinase PFKFB3 with an IC50 of 0.19 μM .
|
-
- HY-N0390S3
-
|
L-Glutamine-13C5,15N2,d5
L-Glutamic acid 5-amide-13C5,15N2,d5
|
mGluR
Endogenous Metabolite
Ferroptosis
|
Metabolic Disease
|
|
L-Glutamine- 13C5, 15N2,d5 is the deuterium, 13C-, and 15-labeled L-Glutamine. L-Glutamine (L-Glutamic acid 5-amide) is a non-essential amino acid present abundantly throughout the body and involved in many metabolic processes. L-Glutamine provides a source of carbons for oxidation in some cells[1][2].
|
-
- HY-16673
-
|
PSN632408
|
GPR119
|
Metabolic Disease
|
|
PSN632408, a selective, orally active GPR119 agonist, shows similar potency to OEA at both recombinant mouse and human GPR119 receptors (EC50=5.6 and 7.9 uM, respectively). PSN632408 can stimulate β-cell replication and improve islet graft function. PSN632408 has the potential for the research of obesity and related metabolic disorders.
|
-
- HY-116433
-
-
- HY-P4745
-
|
hMCH-1R antagonist 1
|
MCHR1 (GPR24)
|
Metabolic Disease
|
|
hMCH-1R antagonist 1 (Compound 30) is an effective and selective antagonist of human melanin-concentrating hormone receptor 1 (hMCHR1) with an KB value of 3.6 nM. HMCH-1R antagonist 1 can bind to hMCHR1 and hMCHR2 with IC50 values of 65 nM and 49 nM, respectively. HMCH-1R antagonistist 1 can be used for metabolic research.
|
-
- HY-107580
-
-
- HY-B0227A
-
|
Ketoprofen (lysinate)
RP-19583 (lysinate)
|
COX
|
Metabolic Disease
Inflammation/Immunology
|
|
Ketoprofen (RP-19583) lysinate is a non-steroidal anti-inflammatory agent. Ketoprofen lysinate can inhibit the activity of cyclooxygenase with IC50 values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity.
|
-
- HY-135880
-
-
- HY-135880A
-
-
- HY-124822
-
|
COH-SR4
|
AMPK
|
Cancer
Metabolic Disease
|
|
COH-SR4 is an AMPK activator. COH-SR4 shows potent anti-proliferative activities against leukemia, melanoma, breast and lung cancers. COH-SR4 inhibits adipocyte differentiation via AMPK activation. COH-SR4 can be used for the research of obesity and related metabolic disorders.
|
-
- HY-B2176S
-
|
ATP-13C10,15N5
Adenosine 5'-triphosphate-13C10,15N5
|
Endogenous Metabolite
|
|
|
ATP- 13C10, 15N5 is the 13C and 15N labeled ATP[1]. ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation[2][3].
|
-
- HY-B0345AS
-
|
ATP-18O4 disodium salt
|
Endogenous Metabolite
|
|
|
ATP- 18O4 (disodium salt) is the 18O labeled ATP disodium salt[1]. ATP disodium salt (Adenosine 5'-triphosphate disodium salt) is a central component of energy storage and metabolism in vivo, provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP disodium salt is an important endogenous signaling molecule in immunity and inflammation[2][3].
|
-
- HY-B2246S
-
|
L-Carnitine-d9 chloride
(R)-Carnitine-d9 (chloride); Levocarnitine-d9 (chloride)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Carnitine-d9 (chloride)e is the deuterium labeled L-Carnitine chloride. L-Carnitine chloride, a highly polar, small zwitterion, is an essential co-factor for the mitochondrial β-oxidation pathway. L-Carnitine chloride functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-Carnitine chloride is an antioxidant. L-Carnitine chloride can ameliorate metabolic imbalances in many inborn errors of metabolism[1][2][3].
|
-
- HY-100560
-
|
Abscisic acid
(S)-(+)-Abscisic acid; ABA
|
Endogenous Metabolite
Proton Pump
|
Metabolic Disease
|
|
Abscisic acid ((S)-(+)-Abscisic acid), an orally active phytohormone in fruits and vegetables, is an endogenously produced mammalian hormone. Abscisic acid is a growth inhibitor and can regulate many aspects of plant growth and development. Abscisic acid inhibits proton pump (H +-ATPase) and leads to the plasma membrane depolarization in a Ca 2+-dependent manner. Abscisic acid, a LANCL2 natural ligand, is a potent insulin-sensitizing compound and has the potential for pre-diabetes, type 2 diabetes and metabolic syndrome.
|
-
- HY-116771A
-
|
CL 316243
|
Adrenergic Receptor
|
Metabolic Disease
|
|
CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors.CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence.
|
-
- HY-112584
-
|
JBSNF-000088
6-Methoxynicotinamide
|
Others
|
Metabolic Disease
|
|
JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease.
|
-
- HY-131447
-
|
KY19382
A3051
|
GSK-3
Wnt
β-catenin
|
Metabolic Disease
|
|
KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases.
|
-
- HY-N0680S1
-
-
- HY-121557
-
-
- HY-N0680S2
-
-
- HY-103342
-
-
- HY-B0227
-
|
Ketoprofen
RP-19583
|
COX
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Ketoprofen (RP-19583) is a non-steroidal anti-inflammatory agent. Ketoprofen can inhibits the activity of cyclooxygenase with IC50 values of 2 nM (COX-1) and 26 nM (COX-2). which is potential in the research of inflammation, immunology, and metabolic disease such as obesity.
|
-
- HY-N0680S
-
-
- HY-128604
-
|
XY101
|
ROR
|
Cancer
|
|
XY101 is a potent, selective, metabolically stable and orally available RORγ inverse agonist with an IC50 of 30 nM and a Kd of 380 nM.
|
-
- HY-N5126
-
|
Juncusol
|
Others
|
Neurological Disease
|
Juncusol, a phenanthrenoid found in Juncus setchuenensis, possesses anxiolytic effect. Juncusol is associated with metabolic changes in cortical serotonin/dopamine levels in Mice.
|
-
- HY-N0680S3
-
-
- HY-N0035
-
-
- HY-145852
-
-
- HY-N7814
-
-
- HY-113043
-
|
Galactonic acid
|
Endogenous Metabolite
|
Others
|
|
Galactonic acid is a sugar acid that is a metabolic breakdown product of galactose. Galactose dehydrogenase is responsible for converting galactose to galactonolactone, which then spontaneously or enzymatically converts to galactonic acid.
|
-
- HY-124314
-
|
LEI-106
|
MAGL
|
Metabolic Disease
|
|
LEI-106 is a potent, dual sn-1-Diacylglycerol lipase α (DAGL-α)/ABHD6 inhibitor with an IC50 of 18 nM for DAGL-α and a Ki of 0.8 μM for ABHD6. LEI-106 inhibits the hydrolysis of [ 14C]-sn-1-oleoyl-2-arachidonoyl-glycerol, the natural substrate of DAGL-α, with a Ki of 0.7 μM.
|
-
- HY-115688
-
-
- HY-114293
-
|
Acetyl coenzyme A
Acetyl-CoA
|
Endogenous Metabolite
Autophagy
|
Metabolic Disease
Cardiovascular Disease
|
|
Acetyl-coenzyme A (Acetyl-CoA) is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A is also a key precursor of lipid synthesis.
|
-
- HY-137808
-
|
Succinyl-Coenzyme A sodium
Succinyl-CoA sodium
|
Endogenous Metabolite
|
Metabolic Disease
Neurological Disease
|
|
Succinyl-Coenzyme A (Succinyl-CoA) sodium is an intermediate of the citric acid cycle. Succinyl-Coenzyme A sodium can be converted to succinic acid and can also combines with glycine to form δ-ALA to synthesize porphyrins (heme). Succinyl-Coenzyme A sodium can be used in the study of metabolic, neurological and haematological abnormalities (such as porphyrias) caused by nutritional vitamin B12 deficiency (resulting in a deficiency in Succinyl-Coenzyme A synthesis).
|
-
- HY-N6932
-
-
- HY-B1692
-
-
- HY-136386
-
-
- HY-Y0418S4
-
|
Dulcite-d2
Dulcitol-d2; Melampyrit-d2; NSC 1944-d2
|
Endogenous Metabolite
|
Others
|
|
Dulcite-d2 is the deuterium labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].
|
-
- HY-Y0418S
-
|
Dulcite-13C
Dulcitol-13C; Melampyrit-13C; NSC 1944-13C
|
Endogenous Metabolite
|
Others
|
|
Dulcite- 13C is the 13C labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].
|
-
- HY-13507
-
|
Lumiracoxib
COX-189
|
COX
|
Cancer
Metabolic Disease
Inflammation/Immunology
|
|
Lumiracoxib is a potent,selective and orally active COX-2 inhibitor with a Ki value of 0.06 μM. Lumiracoxib acts as a nonselective NSAID with anti-inflammatory, analgesic and antipyretic activities. Lumiracoxib can be used for osteoarthritis and bone cancer research.
|
-
- HY-150508
-
|
MK-0159
|
CD38
|
Metabolic Disease
Cardiovascular Disease
|
|
MK-0159 (compound 37) is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD + (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
|
-
- HY-B2227B
-
|
Lactate sodium
Lactic acid sodium
|
Others
|
Metabolic Disease
|
|
Lactate (Lactic acid) sodium is the product of glycogenolysis and glycolysis. Lactate (Lactic acid) sodium is an organic salt that is mainly used as a buffer and pH adjuster for injection solutions. Lactate sodium can be metabolized by the body into sodium bicarbonate, which in turn acts to increase the pH of the blood. Lactate sodium is used to improve metabolic acidosis and hypovolemic states. In terms of pharmaceutical preparations, Lactate sodium is often used in combination with sodium chloride, glucose, etc. to form normal saline or compound liquid intravenous injection. Lactate sodium also has antimicrobial activity, which can be used as a food preservative.
|
-
- HY-113596A
-
|
Acetyl coenzyme A lithium
Acetyl-CoA lithium
|
Endogenous Metabolite
Autophagy
|
Metabolic Disease
Cardiovascular Disease
|
|
Acetyl-coenzyme A (Acetyl-CoA) lithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A lithium, regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A lithium is also a key precursor of lipid synthesis.
|
-
- HY-114293A
-
|
Acetyl coenzyme A trilithium
Acetyl-CoA trilithium
|
Endogenous Metabolite
Autophagy
|
Metabolic Disease
Cardiovascular Disease
|
|
Acetyl-coenzyme A (Acetyl-CoA) trilithium is a membrane-impermeant central metabolic intermediate, participates in the TCA cycle and oxidative phosphorylation metabolism. Acetyl-coenzyme A trilithium regulates various cellular mechanisms by providing (sole donor) acetyl groups to target amino acid residues for post-translational acetylation reactions of proteins. Acetyl Coenzyme A trilithium is also a key precursor of lipid synthesis.
|
-
- HY-15286
-
|
Sodium 4-pentynoate
|
Others
|
Others
|
|
Sodium 4-pentynoate is a alkynylacetate analogue, can be metabolically incorporated onto cellular proteins through biosynthetic mechanisms for profiling of acetylated proteins in diverse cell types.
|
-
- HY-76937
-
|
Impurity of Doxercalciferol
|
VD/VDR
|
Endocrinology
|
|
Impurity of Doxercalciferol is an impurity of doxercalciferol, which is a synthetic analog of ergocalciferol (vitamin D2), used as a agent for secondary hyperparathyroidism and metabolic bone disease, and it suppresses parathyroid synthesis and secretion.
|
-
- HY-118567
-
|
Bis(maltolato)oxovanadium(IV)
BMOV
|
SHP2
Phosphatase
|
Metabolic Disease
|
|
Bis(maltolato)oxovanadium(IV) (BMOV) is a potent, reversible, competitive and orally active pan-PTP (protein tyrosine phosphatases) inhibitor. Bis(maltolato)oxovanadium(IV) inhibits HCPTPA, PTP1B, HPTPβ and SHP2 with IC50s of 126 nM, 109 nM, 26 nM and 201 nM, respectively. Bis(maltolato)oxovanadium(IV) is a potent insulin sensitizer.
|
-
- HY-N0680S5
-
-
- HY-W012241S1
-
|
Dodecanedioic acid-d4
|
Endogenous Metabolite
|
Others
|
|
Dodecanedioic acid-d4 is the deuterium labeled Dodecanedioic acid[1]. Dodecanedioic acid (C12) is a dicarboxylic acid with a metabolic pathway intermediate to those of lipids and carbohydrates[2].
|
-
- HY-122427
-
|
Xylocytidine
|
Nucleoside Antimetabolite/Analog
|
Cancer
|
|
Xylocytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities.
|
-
- HY-N0667S5
-
-
- HY-W012241S
-
|
Dodecanedioic acid-d20
|
Endogenous Metabolite
|
Others
|
|
Dodecanedioic acid-d20 is the deuterium labeled Dodecanedioic acid[1]. Dodecanedioic acid (C12) is a dicarboxylic acid with a metabolic pathway intermediate to those of lipids and carbohydrates[2].
|
-
- HY-12813
-
-
- HY-N11507
-
|
Tibesaikosaponin V
TKV
|
PPAR
|
Metabolic Disease
|
|
Tibesaikosaponin V (TKV) is a triterpene diglycoside, which can be isolated from the methanol extract of the roots of Bupleurum chinense DC.. Tibesaikosaponin V inhibits lipid accumulation and triacylglycerol content occurred without cytotoxicity to adipocytes. Tibesaikosaponin V suppresses the mRNA expression of nuclear transcription factors, such as peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα). Tibesaikosaponin V inhibits 3T3-L1 preadipocyte differentiation. Tibesaikosaponin V can be used fro research of obesity and its associated metabolic disorders.
|
-
- HY-B0218
-
|
Orlistat
Tetrahydrolipstatin; Ro-18-0647
|
Fatty Acid Synthase (FASN)
Apoptosis
|
Metabolic Disease
Cancer
|
|
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect.
|
-
- HY-N2447
-
|
Amarogentin
|
AMPK
Apoptosis
|
Cancer
Metabolic Disease
|
|
Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK.
|
-
- HY-Y0418S3
-
|
Dulcite-13C-3
Dulcitol-13C-3; Melampyrit-13C-3; NSC 1944-13C-3
|
Endogenous Metabolite
|
Others
|
|
Dulcite- 13C-3 is the 13C labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].
|
-
- HY-A0081
-
-
- HY-102036
-
|
G-744
|
Btk
|
Inflammation/Immunology
|
|
G-744 is a highly potent, selective and orally active Btk inhibitor with an IC50 of 2 nM. G-744 is metabolically stable, well tolerated and efficacious to treat arthritis.
|
-
- HY-Y0418S1
-
|
Dulcite-13C-1
Dulcitol-13C-1; Melampyrit-13C-1; NSC 1944-13C-1
|
Endogenous Metabolite
|
Others
|
|
Dulcite- 13C-1 is the 13C labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].
|
-
- HY-Y0418S2
-
|
Dulcite-13C-2
Dulcitol-13C-2; Melampyrit-13C-2; NSC 1944-13C-2
|
Endogenous Metabolite
|
Others
|
|
Dulcite- 13C-2 is the 13C labeled Dulcite. Dulcite is a sugar alcohol with a slightly sweet taste which is a metabolic breakdown product of galact[1][2].
|
-
- HY-P1065A
-
|
Apelin-36(rat, mouse) TFA
|
HIV
|
Infection
Metabolic Disease
Cardiovascular Disease
|
|
Apelin-36(rat, mouse) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) TFA binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) TFA blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ.
|
-
- HY-13012G
-
|
RepSox
E-616452; SJN 2511
|
TGF-β Receptor
|
Metabolic Disease
|
|
RepSox (E-616452) (GMP) is a RepSox (HY-13012) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. RepSox is a potent and selective TGF-β-RI/ALK5 inhibitor.
|
-
- HY-N0667S2
-
|
L-Asparagine-15N2 monohydrate
(-)-Asparagine-15N2 (monohydrate); Asn-15N2 (monohydrate); Asparamide-15N2 (monohydrate)
|
Endogenous Metabolite
|
Neurological Disease
|
|
L-Asparagine- 15N2 (monohydrate) is the 15N-labeled L-Asparagine. L-Asparagine ((-)-Asparagine) is a non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue.
|
-
- HY-N0667S3
-
|
L-Asparagine-13C4 monohydrate
(-)-Asparagine-13C4 (monohydrate); Asn-13C4 (monohydrate); Asparamide-13C4 (monohydrate)
|
Endogenous Metabolite
|
Neurological Disease
|
|
L-Asparagine- 13C4 (monohydrate) is the 13C-labeled L-Asparagine. L-Asparagine ((-)-Asparagine) is a non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue.
|
-
- HY-103479
-
|
GOAT-IN-1
|
Acyltransferase
|
Cancer
Metabolic Disease
Neurological Disease
Cardiovascular Disease
|
|
GOAT-IN-1 is an inhibitor of ghrelin O-acyltransferase (GOAT), which could be useful for the prophylaxis or treatment of obesity, diabetes, hyperlipidemia, metabolic, non-alcoholic fatty liver, steatohepatitis, sarcopenia, appetite control, alcohol/narcotic dependence, Alzheimer’s disease, Parkinson’s disease, cerebrovascular dementia, cerebral apoplexy, cerebral infarction, cardic disease, some kind of tumors.
|
-
- HY-113327
-
-
- HY-W400159
-
-
- HY-B1192
-
|
Estradiol benzoate
β-Estradiol 3-benzoate; 17β-Estradiol 3-benzoate
|
Estrogen Receptor/ERR
|
Endocrinology
Cancer
|
|
Estradiol Benzoate (β-Estradiol 3-benzoate), a proagent of estradiol, acts as a steroid sex hormone. It exhibits mild anabolic and metabolic properties, and increases blood coagulability.
|
-
- HY-N0667S4
-
|
L-Asparagine-4-13C monohydrate
(-)-Asparagine-4-13C (monohydrate); Asn-4-13C (monohydrate); Asparamide-4-13C (monohydrate)
|
Endogenous Metabolite
|
Neurological Disease
|
|
L-Asparagine-4- 13C (monohydrate) is the 13C-labeled L-Asparagine. L-Asparagine ((-)-Asparagine) is a non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue.
|
-
- HY-W578275
-
-
- HY-152694
-
|
5-Vinylcytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Vinylcytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities.
|
-
- HY-152658
-
|
5-Phenylcytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
5-Phenylcytidine is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities.
|
-
- HY-W555551
-
-
- HY-Y1269
-
|
Ammonium chloride, AR, 99.5%
|
Autophagy
|
Cancer
|
|
Ammonium chloride, as a heteropolar compound with pH value regulation, can cause intracellular alkalization and metabolic acidosis thus effecting enzymatic activity and influencing the process of biological system. Ammonium chloride is an autophagy inhibitor.
|
-
- HY-146214
-
|
CDK4/6-IN-13
|
CDK
|
Cancer
|
|
As a cdk4/6 inhibitor. Compounds 10B and 10C showed low nanomolar activity, ideal antiproliferative activity, excellent metabolic properties and acceptable pharmacokinetics on cdk4/6.
|
-
- HY-B0399S
-
|
L-Carnitine-d9
(R)-Carnitine-d9; Levocarnitine-d9
|
Endogenous Metabolite
|
Metabolic Disease
Neurological Disease
|
|
L-Carnitine-d9 is the deuterium labeled L-Carnitine. L-Carnitine (Levocarnitine) is an endogenous molecule involved in fatty acid metabolism, biosynthesized within the human body using amino acids: L-lysine and L-methionine, as substrates. L-Carnitine functions to transport long chain fatty acyl-CoAs into the mitochondria for degradation by β-oxidation. L-carnitine can ameliorate metabolic imbalances in many inborn errors of metabolism[1][2].
|
-
- HY-N6626
-
-
- HY-121390
-
|
Lasiocarpine
|
Endogenous Metabolite
|
Cancer
|
|
Lasiocarpine, a hepatotoxic pyrrolizidine alkaloid (PA), causes fatal liver veno-occlusive disease in vivo. Lasiocarpine is toxic only after its metabolic conversion to the toxic intermediate, including dehydrolasiocarpine and N-oxide.
|
-
- HY-154699
-
-
- HY-153077
-
-
- HY-152787
-
-
- HY-152784
-
-
- HY-152394
-
-
- HY-152446
-
-
- HY-152789
-
-
- HY-154150
-
-
- HY-P0203
-
|
α-CGRP, rat
|
CGRP Receptor
|
Metabolic Disease
Inflammation/Immunology
Cardiovascular Disease
|
|
α-CGRP, rat, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP, rat can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP, rat has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies.
|
-
- HY-101032
-
|
RIPA-56
|
RIP kinase
|
Inflammation/Immunology
|
|
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting
protein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.
|
-
- HY-W115186
-
-
- HY-154413
-
-
- HY-W009538
-
-
- HY-152382
-
-
- HY-B0863S
-
|
Glyphosate-d2
|
Apoptosis
Autophagy
|
|
|
Glyphosate-d2 is the deuterium labeled Glyphosate. Glyphosate is an herbicidal derivative of the amino acid glycine. Glyphosate targets and blocks a plant metabolic pathway not found in animals, the shikimate pathway, required for the synthesis of aromatic amino acids in plants[1].
|
-
- HY-W130466
-
|
N4-Methylcytidine
|
Nucleoside Antimetabolite/Analog
|
Others
|
|
N4-Methylcytidine (Nsc518744) is a cytidine nucleoside analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities.
|
-
- HY-A0213
-
|
Tiludronate
Tiludronic acid
|
Proton Pump
|
Inflammation/Immunology
|
|
Tiludronate (Tiludronic Acid), an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.
|
-
- HY-136933
-
|
Gitoxin
|
Na+/K+ ATPase
|
Cardiovascular Disease
|
|
Gitoxin, a Na +/K +-ATPase inhibitor, usually appears as a result of metabolic degradation of Digitoxin, is just the hydroxyl (ZOH) group close to the C-17β position, which changes the pharmacokinetics and pharmacodynamics of these substances considerably.
|
-
- HY-101904
-
-
- HY-P0203A
-
|
α-CGRP, rat TFA
|
CGRP Receptor
|
Metabolic Disease
Inflammation/Immunology
Cardiovascular Disease
|
|
α-CGRP, rat TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP, rat TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP, rat TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies.
|
-
- HY-131445A
-
|
SS-RJW100
|
Others
|
Metabolic Disease
Inflammation/Immunology
|
|
SS-RJW100 is a enantiomer of RJW100, which is a racemic agonist of nuclear receptor liver receptor homolog 1 (LRH-1) and steroidogenic factor 1 (SF-1). SS-RJW100 promotes recruitment of coregulator protein fragments in vitro, recruits the transcriptional intermediary factor 2 (Tif2) coactivator to LRH-1. SS-RJW100 diminishes LRH-1 allosteric activation networks, shows poor thermal stability.
|
-
- HY-152714
-
-
- HY-W012499S
-
|
N-Acetyl-L-methionine-d3
N-Acetylmethionine-d3
|
Endogenous Metabolite
|
|
|
N-Acetyl-L-methionine-d3 is the deuterium labeled N-Acetyl-L-methionine. N-Acetyl-L-methionine, a human metabolite, is nutritionally and metabolically equivalent to L-methionine. L-methionine is an indispensable amino acid required for normal growth and development[1].
|
-
- HY-N0667S1
-
-
- HY-152360
-
-
- HY-103237
-
|
L-Adenosine
|
Adenosine Deaminase
|
Neurological Disease
|
|
L-Adenosine is a metabolically stable enantiomeric analog and also is a potential probe. L-Adenosine has weakly inhibitory adenosine deaminase (ADA) activity with an Ki value of 385 μM. L-Adenosine can be used for the research of adenosine uptake and accumulation.
|
-
- HY-A0213A
-
|
Tiludronate disodium
Tiludronic acid disodium
|
Proton Pump
|
Inflammation/Immunology
|
|
Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.
|
-
- HY-152528
-
-
- HY-154151
-
-
- HY-15980
-
|
GNF179 (Metabolite)
|
Parasite
|
Infection
|
|
GNF179 metabolite is the metabolite of GNF179, which is an optimized 8,8-dimethyl IP analog that exhibited the potency(4.8 nM against the multidrug resistant strain W2) in vitro metabolic stability and in vivo oral bioavailability.
|
-
- HY-101036
-
|
Choline bitartrate
|
mAChR
Endogenous Metabolite
|
Neurological Disease
Cancer
|
|
Choline bitartrate is a vitamin-like essential nutrient, can affect diseases such as liver disease, atherosclerosis and neurological disorders. Choline bitartrate is a precursor for the neurotransmitter acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism.
|
-
- HY-A0081S
-
|
Fluphenazine-d8 dihydrochloride
|
Dopamine Receptor
|
Neurological Disease
Cancer
|
|
Fluphenazine-d8 (dihydrochloride) is the deuterium labeled Fluphenazine dihydrochloride. Fluphenazine dihydrochloride is a phenothiazine-class D1DR and D2DR inhibitor; used to deliver Fluphenazine to biological systems in studies probing the effects and metabolic fates of this commonly used dopamine antagonist.
|
-
- HY-152406
-
-
- HY-W018772S6
-
|
D-Ribose-d
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose-d is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gly
|
-
- HY-152822
-
-
- HY-152526
-
-
- HY-150684
-
|
GXH-II-052
|
Epigenetic Reader Domain
|
Cancer
|
|
GXH-II-052 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. GXH-II-052 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with Kd values of 28, 9.1, 4.8, 0.6, 8.4, 2.6 nM, respectively. GXH-II-052 shows antiproliferative activity. GXH-II-052 decreases the expression of c-Myc.
|
-
- HY-150683
-
|
NC-III-49-1
|
Epigenetic Reader Domain
|
Cancer
|
|
NC-III-49-1 is a potent bivalent bromodomain and extraterminal domain (BET) inhibitor. NC-III-49-1 shows binding potential for BRD4-1, BRD4-2, BRD4-T, BRDT-1, BRDT-2, BRDT-T with Kd values of 0.095, 0.32, 0.29, 0.089, 5.5, 0.058 nM, respectively. NC-III-49-1 shows antiproliferative activity. NC-III-49-1 decreases the expression of c-Myc.
|
-
- HY-146616
-
|
GLS1 Inhibitor-3
|
Glutaminase
|
Cancer
|
|
GLS1 Inhibitor-3 (compound C147) is a potent GLS1 inhibitor with an IC50 of 27.98 nM. GLS1 Inhibitor-3 shows antiproliferative activity.
|
-
- HY-120438
-
|
TASP0415914
|
PI3K
Akt
|
Inflammation/Immunology
|
|
TASP0415914 is a potent and orally active PI3Kγ inhibitor with an IC50 of 29 nM. TASP0415914 also shows potent Akt inhibitory activities with an IC50 of 294 nM. TASP0415914 can be used for inflammatory diseases research.
|
-
- HY-W001189
-
|
1,3-Dithiane
|
Bacterial
Endogenous Metabolite
|
Infection
|
|
1,3-Dithiane is a protected formaldehyde anion equivalent that could serve as a useful labeled synthon. 1,3-Dithiane is also a sulfur-containing Maillard reaction products (MRPs) found in boiled beef extracts. 1,3-Dithiane shows a potent direct-acting mutagenicity toward S. typhimurium TA98 and TA100.
|
-
- HY-151879
-
-
- HY-117391
-
-
- HY-10585
-
-
- HY-10585A
-
-
- HY-152483
-
-
- HY-W114787
-
-
- HY-152300
-
-
- HY-N0304
-
|
L-DOPA
Levodopa; 3,4-Dihydroxyphenylalanine
|
Dopamine Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease.
|
-
- HY-154480
-
-
- HY-W018772S1
-
|
D-Ribose-13C
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose- 13C is the 13C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati
|
-
- HY-B0863S2
-
|
Glyphosate-d2-1
|
Apoptosis
Autophagy
|
Cancer
|
|
Glyphosate-d2-1 is the deuterium labeled Glyphosate[1]. Glyphosate is an herbicidal derivative of the amino acid glycine. Glyphosate targets and blocks a plant metabolic pathway not found in animals, the shikimate pathway, required for the synthesis of aromatic amino acids in plants[2].
|
-
- HY-W018772S
-
|
D-Ribose-18O
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose- 18O is the 18O labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glycati
|
-
- HY-W018772S9
-
|
D-Ribose-d-3
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose-d-3 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g
|
-
- HY-152480
-
-
- HY-W018772S12
-
|
D-Ribose-d6
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose-d6 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
|
-
- HY-154397
-
-
- HY-W018772S10
-
|
D-Ribose-d2
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose-d2 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
|
-
- HY-W018772S14
-
|
D-Ribose-d5
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose-d5 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein gl
|
-
- HY-118091A
-
|
Bexlosteride
LY300502
|
Others
|
Cancer
|
|
Bexlosteride (LY300502) is a benzoquinolinone human type I 5α-reductase inhibitor. Bexlosteride shows metabolic inhibitory, antiproliferative, and antisecretory effects in LNCaP human prostatic adenocarcinoma cell cultures. Bexlosteride can be used for the research of prostatic cancer.
|
-
- HY-W018772S8
-
|
D-Ribose-d-2
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose-d-2 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g
|
-
- HY-136059
-
-
- HY-W018772S7
-
|
D-Ribose-d-1
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose-d-1 is the deuterium labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein g
|
-
- HY-101971
-
|
AZ PFKFB3 26
|
Autophagy
|
Cancer
|
|
AZ PFKFB3 26 is a potent and selective inhibitor of the metabolic kinase PFKFB3 with an IC50 of 23 nM. AZ PFKFB3 26 inhibits PFKFB1 and PFKFB2 with IC50s of 2.06 and 0.384 μM, respectively.
|
-
- HY-W128788A
-
-
- HY-129039
-
-
- HY-N6807
-
|
Elemicin
|
Stearoyl-CoA Desaturase (SCD)
Influenza Virus
|
Cancer
Infection
|
|
Elemicin is a alkenylbenzene widely distributed in many herbs and spices. Elemicin inhibits Stearoyl-CoA Desaturase 1 (SCD1) by metabolic activation. Elemicin is one of the main components in aromatic food and has antimicrobial, antioxidant, and antiviral activities. Elemicin possesses genotoxicity and carcinogenicity.
|
-
- HY-D1598
-
|
Sulfo-CY3 tetrazine potassium
|
Fluorescent Dye
|
Others
|
|
Sulfo-CY3 tetrazine potassium is a sulfo-Cyanine3 derivative that contains methyltetrazine moiety (Ex=548 nm, Em=563 nm). Sulfo-CY3 tetrazine potassium can be used for the labeling of metabolically engineered cell-surface glycoconjugates.
|
-
- HY-104039
-
-
- HY-152763
-
-
- HY-109001
-
|
Alicapistat
ABT-957
|
Proteasome
|
Neurological Disease
|
|
Alicapistat (ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential application of Alzheimer's disease (AD). Alicapistat mitigates the metabolic liability of carbonyl reduction and inhibits calpain 1 with an IC50 value of 395 nM.
|
-
- HY-N0304A
-
|
L-DOPA sodium
Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium
|
Dopamine Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research.
|
-
- HY-10585B
-
-
- HY-150701
-
-
- HY-144686
-
|
ATM Inhibitor-3
|
ATM/ATR
PI3K
mTOR
|
Cancer
|
|
ATM Inhibitor-3 (compound 34) is a potent and selective ATM inhibitor, with an IC50 of 0.71 nM. ATM Inhibitor-3 shows inhibition of PI3K kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability.
|
-
- HY-144723
-
|
Antitubercular agent-13
|
Bacterial
|
Infection
|
|
Antitubercular agent-13 (Compound 3d) is an antitubercular agent with MIC values of 0.007 µg/mL and 1.851 µg/mL against MTB H37Rv and MDR-MTB 16833, respectively. Antitubercular agent-13 shows metabolic instability.
|
-
- HY-152811
-
-
- HY-W411295
-
-
- HY-W013136
-
|
Triheptanoin
|
Others
|
Neurological Disease
|
|
Triheptanoin (Propane-1,2,3-triyl triheptanoate) is a synthetic medium-chain triglyceride (MCT) consisting of three odd-chain 7-carbon (heptanoate) fatty acids on a glycerol backbone. Triheptanoin can be used for the research of inherited metabolic disorders.
|
-
- HY-W009749
-
|
L-Cystathionine
|
Endogenous Metabolite
Apoptosis
|
Cardiovascular Disease
|
|
L-Cystathionine is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs). L-Cystathionine plays an important role in cardiovascular protection.
|
-
- HY-B1192S
-
|
Estradiol benzoate-d3
β-Estradiol 3-benzoate-d3; 17β-Estradiol 3-benzoate-d3
|
Estrogen Receptor/ERR
|
|
|
Estradiol benzoate-d3 is the deuterium labeled Estradiol benzoate. Estradiol Benzoate (β-Estradiol 3-benzoate), a proagent of estradiol, acts as a steroid sex hormone. It exhibits mild anabolic and metabolic properties, and increases blood coagulability[1][2][3][4].
|
-
- HY-W018772S2
-
|
D-Ribose-13C-1
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose- 13C-1 is the 13C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca
|
-
- HY-Y1091
-
|
D-Lysine
|
Endogenous Metabolite
|
Others
|
|
D-Lysine is a useful raw material employed as an analog of lutenizing-hormone-releasing hormone and as a agent carrier in the form of polylysine. D-Lysine decreases renal uptake of radioactivity during scintigraphy and PRRT with low toxicity. D-Lysine not interferes with the natural amino acid metabolic balance.
|
-
- HY-W018772S4
-
|
D-Ribose-13C-3
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose- 13C-3 is the 13C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca
|
-
- HY-154414
-
-
- HY-W018772S5
-
|
D-Ribose-13C-4
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose- 13C-4 is the 13C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca
|
-
- HY-W018772S3
-
|
D-Ribose-13C-2
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose- 13C-2 is the 13C labeled D-Ribose. D-Ribose is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose is active in protein glyca
|
-
- HY-154019
-
-
- HY-P1066A
-
|
Apelin-17(human, bovine) TFA
|
HIV
|
Infection
|
|
Apelin-17(human, bovine) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) TFA binds to human APJ receptors expressed in HEK 293 cells (pIC50=9.02). Apelin-17(human, bovine) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
|
-
- HY-135883
-
-
- HY-141475
-
|
Acetoacetyl coenzyme A sodium
|
Endogenous Metabolite
|
Others
|
|
Acetoacetyl coenzyme A sodium is a central endogenous metabolite. The Km at pH 7.5 for Acetoacetyl coenzyme A sodium is 1.10 mM. Acetoacetyl coenzyme A sodium can be used for the synthesis of phosphotransbutyrylase (PTB) and poly-3-hydroxybutyrate (PHB).
|
-
- HY-118402
-
|
PD 119819
|
Dopamine Receptor
|
Neurological Disease
|
|
PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis.
|
-
- HY-P1066
-
|
Apelin-17(human, bovine)
|
HIV
|
Infection
|
|
Apelin-17(human, bovine) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) binds to human APJ receptors expressed in HEK 293 cells (pIC50=9.02). Apelin-17(human, bovine) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
|
-
- HY-132392S
-
-
- HY-B1779S5
-
|
Sucrose-13C6
D-(+)-Saccharose-13C6
|
Endogenous Metabolite
|
|
|
Sucrose- 13C6 is the 13C labeled Sucrose[1]. Sucrose (D-(+)-Saccharose) is a disaccharide which is composed of two monosaccharides, glucose and fructose. Sucrose?can be applied in some animal models, including metabolic disease, obesity,?diet on preference,?and diabetes, et al[2].
|
-
- HY-W018772
-
|
D-Ribose(mixture of isomers)
|
Endogenous Metabolite
|
Inflammation/Immunology
Cancer
|
|
D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.
|
-
- HY-152705
-
-
- HY-115688A
-
|
(S)-TXNIP-IN-1
|
Others
|
Others
|
|
(S)-TXNIP-IN-1 is the less active S-enantiomer of TXNIP-IN-1 (HY-115688). TXNIP-IN-1 is a TXNIP-TRX complex inhibitor which can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease
|
-
- HY-146268
-
|
CaMKIIα-IN-1
|
CaMK
|
Neurological Disease
|
|
CaMKIIα-IN-1 (Compound 4d) is an orally active Ca 2+/calmodulin-dependent protein kinase II α (CaMKIIα) inhibitor with a KD of 219 nM for CaMKIIα WT hub. CaMKIIα-IN-1 has good metabolic stability.
|
-
- HY-W048504
-
-
- HY-151957
-
|
Antitubercular agent 34
|
Bacterial
|
Infection
|
|
Antitubercular agent 34 (compound 42g) is an antitubercular agent. Antitubercular agent 34 inhibits the growth of MtbH37Rv with a MIC90 value of 1.25 μg/mL with the ability of escaping metabolic degradation by human liver microsomes. Antitubercular agent 34 can be used for the research of tuberculosis.
|
-
- HY-N0667S
-
-
- HY-149242
-
|
MAO-B-IN-20
|
Monoamine Oxidase
|
Neurological Disease
|
|
MAO-B-IN-20 (Compound C14) is a potent MAO-B inhibitor with an IC50 of 0.037 μM. MAO-B-IN-20 displays good metabolic stability and brain-blood barrier permeability. MAO-B-IN-20 can be used for the research of Parkinson's disease.
|
-
- HY-B1703
-
|
Nifursol
|
Bacterial
Antibiotic
|
Infection
|
|
Nifursol is a potent and orally active veterinary antibiotic for the prevention of histomoniasis. Nifursol rapidly metabolizes to form the metabolic marker 3,5-dinitrosalicyclic acid hydrazide (DNSAH) which can persist for a long time. Nifursol is widely used for the research of Escherichia Gastroenteropathy in poultry, fowl and aquatic animal.
|
-
- HY-152976
-
-
- HY-152978
-
|
2'-Deoxy-5'-O-DMT-N4-Fmoc-5-methylcytidine
|
Others
|
Others
|
|
2'-Deoxy-5'-O-DMT-N4-Fmoc-5-methylcytidine is a cytidine analog. Cytidine analogs have a mechanism of inhibiting DNA methyltransferases (such as Zebularine, HY-13420), and have potential anti-metabolic and anti-tumor activities.
|
-
- HY-N8022
-
|
Lucidin primeveroside
Lucidin 3-O-β-primeveroside
|
Biochemical Assay Reagents
|
Cancer
|
|
Lucidin primeveroside (Lucidin 3-O-β-primeveroside) is an anthraquinone derivative present in madder root, which has been used as a coloring agent and food additive. Lucidin primeveroside can be metabolically converted to genotoxic compound Lucidin, which subsequently forms lucidin-specific DNA adducts.
|
-
- HY-144829
-
|
PI3Kα-IN-5
|
PI3K
mTOR
|
Cancer
|
|
PI3Kα-IN-5 (Compound 6ab) is a potent PI3Kα inhibitor with an IC50 of 0.7 nM. PI3Kα-IN-5 shows antitumor activity with good metabolic stabilities and safety profiles.
|
-
- HY-154000
-
-
- HY-N0304S
-
|
L-DOPA-d6
Levodopa-d6; 3,4-Dihydroxyphenylalanine-d6
|
Dopamine Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].
|
-
- HY-128428
-
|
Carboprost
15(S)-15-Methyl Prostaglandin F2α; 15-Methyl-PGF2α
|
Prostaglandin Receptor
|
Endocrinology
|
|
Carboprost (15(S)-15-Methyl Prostaglandin F2α) is a metabolically stable synthetic analog of prostaglandin F2α. Carboprost stimulates uterine contractions and induces abortion. Carboprost is used for postpartum hemorrhage due to uterine atony and for the termination of pregnancy in the second trimester.
|
-
- HY-146121
-
|
Antitubercular agent-26
|
Bacterial
|
Infection
|
|
Antitubercular agent-26 (Compound 32) is an orally active anti-tubercular agent with an extracellular IC50 of 0.50 μM and an intracellular IC50 of 0.51 μM against M. tuberculosis H37Rv. Antitubercular agent-26 shows good metabolic stability, low risk of cardiotoxicity and no genotoxicity.
|
-
- HY-139047
-
|
SW157765
|
GLUT
|
Cancer
|
|
SW157765 is a selective non-canonical glucose transporter GLUT8 (SLC2A8) inhibitor. KRAS/KEAP1 double mutant NSCLC cells are selectively sensitive to the SW157765, due to the convergent consequences of dual KRAS and NRF2 modulation of metabolic and xenobiotic gene regulatory programs.
|
-
- HY-112613
-
|
UCB9608
|
PI4K
|
Inflammation/Immunology
|
|
UCB9608 is a potent, selective and orally active PI4KIIIβ inhibitor, with an IC50 of 11 nM, selective over PI3KC2 α, β, and γ lipid kinases. UCB9608 improves metabolic stability and exhibits excellent pharmacokinetic profile, acts as a potent immunosuppressive agent.
|
-
- HY-154077
-
-
- HY-A0213AS
-
|
Tiludronate-d5 sodium
Tiludronic acid-d5 (sodium)
|
Proton Pump
|
Inflammation/Immunology
|
|
Tiludronate-d5 (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].
|
-
- HY-N0304S2
-
|
L-DOPA-13C
|
Dopamine Receptor
Endogenous Metabolite
|
|
|
L-DOPA- 13C is the 13C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].
|
-
- HY-113629
-
|
2-Keto-D-Glucose
D-Glucosone; D-Arabino-hexos-2-ulose
|
Drug Metabolite
|
Infection
|
|
2-Keto-D-Glucose (D-Glucosone) is a key intermediate in a secondary metabolic pathway leading to the antibiotic Cortalcerone. 2-Keto-D-Glucose is also an intermediate in the conversion of D-glucose into D-fructose. 2-Keto-D-Glucose is found in various natural sources, including fungi, algae, and shellfish.
|
-
- HY-152310
-
-
- HY-152979
-
-
- HY-152219
-
|
CLK1-IN-2
|
CDK
|
Cancer
Infection
|
|
CLK1-IN-2 is metabolically stable Clk1 inhibitor. CLK1-IN-2 has selectivity for Clk1 with an IC50 value of 1.7 nM. CLK1-IN-2 can be used for the research of tumour, Duchenne's muscular dystrophy and viral infections such as HIV-1 and influenza.
|
-
- HY-148075
-
|
PI4KIIIbeta-IN-11
|
PI4K
|
Infection
|
|
PI4KIIIbeta-IN-11 is an inhibitor of PI4KIIIβ, with a mean pIC50 value of at least 9.1. PI4KIIIβ plays a key role in diseases research of RNA viruses and Plasmodium falciparum.
|
-
- HY-145695
-
-
- HY-126321
-
|
RORγt agonist 1
|
ROR
|
Cancer
|
|
RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC50 of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy.
|
-
- HY-B1703S
-
|
Nifursol-13C6
|
Bacterial
Antibiotic
|
Infection
|
|
Nifursol- 13C6 is the 13C6 labeled Nifursol. Nifursol is a potent and orally active veterinary antibiotic for the prevention of histomoniasis. Nifursol rapidly metabolizes to form the metabolic marker 3,5-dinitrosalicyclic acid hydrazide (DNSAH) which can persist for a long time. Nifursol is widely used for the research of Escherichia Gastroenteropathy in poultry, fowl and aquatic animal.
|
-
- HY-154450
-
-
- HY-143326
-
|
Antibacterial agent 83
|
Bacterial
|
Infection
|
|
Antibacterial agent 83 (compound 17h) displays potent antibacterial activity against various vancomycin-resistant Enterococcus faecalis (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Antibacterial agent 83 can significantly reduce the biofilm formation of MRSA and exhibited promising selectivity. Antibacterial agent 83 is metabolically stable in human liver microsomes.
|
-
- HY-N0304S1
-
|
L-DOPA-d6-1
Levodopa-d6-1; 3,4-Dihydroxyphenylalanine-d6-1
|
Dopamine Receptor
Endogenous Metabolite
|
|
|
L-DOPA-d6-1 is the deuterium labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].
|
-
- HY-113037
-
|
Farnesyl pyrophosphate
Farnesyl diphosphate
|
TRP Channel
Endogenous Metabolite
|
Neurological Disease
|
|
Farnesyl pyrophosphate (Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis.
|
-
- HY-154441
-
-
- HY-144687
-
|
ATM Inhibitor-4
|
ATM/ATR
PI3K
mTOR
|
Cancer
|
|
ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC50 of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of PI3K kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability.
|
-
- HY-B0300
-
|
Penicillamine
D-(-)-Penicillamine
|
Drug Metabolite
|
Inflammation/Immunology
Cancer
|
|
Penicillamine (D-(-)-Penicillamine) is a penicillin metabolic degradation product, can be used as a heavy metal chelator. Penicillamine increases free copper and enhances oxidative stress. Penicillamine has effect of seizures through nitric oxide/NMDA pathways. Penicillamine is a potential immune modulator. Penicillamine can be used for the research of Wilson disease, rheumatoid arthritis, and cystinuria.
|
-
- HY-106225
-
|
Rotigaptide
ZP123
|
Gap Junction Protein
|
Cardiovascular Disease
|
|
Rotigaptide (ZP123) is a novel and specific modulator of connexin 43 (Cx43). Rotigaptide prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress. Rotigaptide is a potent antiarrhythmic peptide (AAP) with improved stability and has the potential for the investigation of cardiac arrhythmias-specifically atrial fibrillation.
|
-
- HY-152468
-
|
Antitumor agent-83
|
Apoptosis
|
Cancer
|
|
Antitumor agent-83 is an activator of pro-apoptotic protein BAX and has significant anti-proliferation effect on tumor cells. Antiumor agent-83 mediates cell Apoptosis by inducing the conformational activation of BAX and has inhibitory effect on A549 cell cycle. Antiumor agent-83 has good metabolic stability and CYPs spectrum in vitro.
|
-
- HY-151958
-
|
Antitubercular agent-35
|
Bacterial
|
Infection
|
|
Antitubercular agent-35 (compound 42l) is an antitubercular agent. Antitubercular agent-35 inhibits the growth of MtbH37Rv and M. Marinum with MIC90 values of 1.25 and 2 μg/mL, respectively. Antitubercular agent-35 shows the ability of escaping metabolic degradation by human liver microsomes. Antitubercular agent-35 can be used for the research of tuberculosis.
|
-
- HY-117507
-
|
U92016A hydrochloride
|
5-HT Receptor
|
Neurological Disease
|
|
U92016A hydrochloride is a potent, metabolically stable, orally acitive 5-HT1A receptor agonist with an exceptionally high degree of intrinsic activity. U92016A hydrochloride binds with high affinity to human 5-HT1A receptors expressed in Chinese hamster ovary cells (Ki=0.2 nM).
|
-
- HY-151964
-
|
FA16
|
Ferroptosis
|
Cancer
|
|
FA16 is a specific ferroptosis inducer (IC50=1.26 μM; HT1080 cells) with metabolic stability, is the derivate of 2-(trifluoromethyl)benzimidazole. FA16 acts by inhibiting cystine/glutamate antiporter (system Xc -), which mediates the exchange of intracellular glutamate and extracellular cystine. FA16 significantly inhibits tumor growth in the HepG2 xenograft model.
|
-
- HY-129084
-
|
Propargylcholine bromide
|
Others
|
Others
|
|
Propargylcholine bromide is a choline analogue containing terminal propargyl that can be incorporated into all classes of Choline-containing phospholipids such as phosphatidylcholine and sphingomyelin, labeling Choline-containing phospholipids. Propargylcholine bromide-labeled phospholipid molecules can be visualized in cells with high sensitivity and spatial resolution. Propargylcholine bromide can be used as a molecular tool to study the biochemical and metabolic processes of Choline-containing phospholipids in cells.
|
-
- HY-147758
-
|
BACE1/2-IN-1
|
Beta-secretase
Amyloid-β
|
Neurological Disease
|
|
BACE1/2-IN-1 (compound 34) is a potent BACE1 and BACE2 inhibitor, with an IC50 of 0.01 and 0.0053 μM, respectively. BACE1/2-IN-1 shows a combination of lower Pgp efflux ratio and improved passive permeability. BACE1/2-IN-1 displays reduced liver microsomal metabolic stability.
|
-
- HY-129101
-
|
(-)-Eseroline fumarate
Eseroline fumarate
|
5-HT Receptor
|
Neurological Disease
|
|
(-)-Eseroline fumarate is a metabolic of Physostigmine (HY-N6608), an AChE inhibitor. (-)-Eseroline fumarate elicits a leakage of lactic acid dehydrogenase (LDH) from cancer cells. (-)-Eseroline fumarate also induces the release of adenine nucleotides and 5-hydroxytryptamine (5-HT) from neuronal cells, thus induce cell death. (-)-Eseroline fumarate inhibits the electrically evoked twitches of the mouse vas deferens and of the guinea-pig ileum.
|
-
- HY-138657
-
|
NCGC00378430
|
Phosphatase
|
Cancer
|
NCGC00378430 is a potent SIX1/EYA2 interaction inhibitor. NCGC00378430 partially reverses transcriptional and metabolic profiles mediated by SIX1 overexpression and reverses SIX1-induced TGF-β signaling and epithelial-mesenchymal transition (EMT). NCGC00378430 inhibits SIX1-mediated breast cancer metastasis in a mouse model.
|
-
- HY-146302
-
|
Antitumor agent-54
|
Apoptosis
|
Cancer
|
|
Antitumor agent-54 (Compound C11) is a 14-3-3η protein inhibitor with a KD of 35 µM. Antitumor agent-54 shows inhibitory activities against several typical human liver cancer cell lines. Antitumor agent-54 induces cell apoptosis and G1-S cell cycle arrest with good metabolic stability.
|
-
- HY-113439
-
|
12-HETE
|
Apoptosis
|
Inflammation/Immunology
Cardiovascular Disease
|
|
12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway.12-HETE has both anti-thrombotic and pro-thrombotic effects. 12-HETE is a neuromodulator.
|
-
- HY-131296
-
|
5-A-RU-PABC-Val-Cit-Fmoc
|
Others
|
Inflammation/Immunology
|
|
5-A-RU-PABC-Val-Cit-Fmoc is the proagent of 5-A-RU. 5-A-RU, a precursor of bacterial Riboflavin, is a mucosal-associated invariant T (MAIT) cells activator. 5-A-RU forms potent MAIT-activating antigens via non-enzymatic reactions with small molecules, such as glyoxal and methylglyoxal, which are derived from other metabolic pathways.
|
-
- HY-146388
-
|
Mtb ATP synthase-IN-1
|
Bacterial
ATP Synthase
|
Infection
|
|
Mtb ATP synthase-IN-1 (compound 6ab) is a potent Mycobacterium tuberculosis (Mtb) ATP synthase inhibitor, with MIC of 0.452-0.499 μg/mL against Mtb. Mtb ATP synthase-IN-1 has good metabolic stability, low cytotoxicity (Vero IC50 > 64 μg/mL), and acceptable oral bioavailability. Mtb ATP synthase-IN-1 can be used for researching anti-mycobacterium.
|
-
- HY-147754
-
|
JAK3/BTK-IN-6
|
Btk
JAK
|
Inflammation/Immunology
|
|
JAK3/BTK-IN-6 (compound 14h) is a potent BTK and JAK3 dual inhibitor, with IC50 values of 0.6 and 0.4 nM, respectively. JAK3/BTK-IN-6 shows good metabolic stability in human liver microsome. JAK3/BTK-IN-6 can be used for hematological and immune diseases research.
|
-
- HY-144632
-
|
Antifungal agent 22
|
Fungal
|
Infection
|
|
Antifungal agent 22 (compound D16) is a potential and orally active antifungal agent for CM (cryptococcal meningitis), with an IC50 of 0.5 μg/mL. Antifungal agent 22 can penetrate the blood-brain barrier and kill the C. neoformans H99 cells by destroying the integrity of fungal cell membranes. Antifungal agent 22 shows selective anti-Cryptococcus activity with good metabolic stability and low cytotoxicity.
|
-
- HY-19762
-
-
- HY-144738
-
|
Dual FAAH/sEH-IN-1
|
Epoxide Hydrolase
FAAH
|
Inflammation/Immunology
|
|
Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual sEH (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC50 values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase.
|
-
- HY-150719
-
-
- HY-P3960
-
|
(Glu2)-TRH
|
Thyroid Hormone Receptor
Endogenous Metabolite
|
Neurological Disease
|
|
(Glu2)-TRH, a metabolically stable analogue of Thyrotropin-releasing hormone (TRH; HY-P0002), is a negative modulator for the cholinergic effect of TRH in the mouse brain. (Glu2)-TRH significantly attenuates TRH-induced hippocampal extracellular acetylcholine release. (Glu2)-TRH is not metabolized by thyroliberinase. (Glu2)-TRH manifests neuroprotective, antidepressant, anticonvulsant in the CNS.
|
-
- HY-109001A
-
|
(1S,2R)-Alicapistat
(1S,2R)-ABT-957
|
Proteasome
|
Neurological Disease
|
|
(1S,2R)-Alicapistat ((1S,2R)-ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential application of Alzheimer's disease (AD). (1S,2R)-Alicapistat mitigates the metabolic liability of carbonyl reduction and inhibits calpain 1 with an IC50 value of 395 nM.
|
-
- HY-146594
-
|
NLRP3-IN-8
|
NOD-like Receptor (NLR)
|
Inflammation/Immunology
|
|
NLRP3-IN-8 (compound 27) is an orally active, directly binding NLRP3 inflammasome inhibitor with an IC50 value of 1.23 μM against IL-1 β. NLRP3-IN-8 has good metabolic stability to liver microsomes (t1/2 = 138.63 min), and has almost no toxicity (against L02: IC50 > 100 μM).
|
-
- HY-100940
-
|
6-Chloromelatonin
|
Melatonin Receptor
|
Endocrinology
|
|
6-Chloromelatonin is a potent melatonin receptor agonist with greater metabolic stability than melatonin. 6-Chloromelatonin compete for [ 3H]-melatonin and 2-[ 125I]-iodomelatonin binding to MT1 receptors (pKi=8.9 and 9.1, respectively). 6-Chloromelatonin compete for [ 3H]-melatonin binding to MT2 receptors (pKi=9.77).
|
-
- HY-N10481
-
|
Aviculin
|
Apoptosis
Caspase
PARP
Bcl-2 Family
|
Cancer
|
|
Aviculin, a lignan glycoside, is a potent anticancer agent. Aviculin reduces metabolic activity on MCF-7 cells below 50%, with an IC50 of 75.47 μM. Aviculin induces breast cancer cell apoptosis through the intrinsic apoptosis pathway. Aviculin increases expression of initiator caspase-9, executioner caspase-7, and poly (ADP-ribose) polymerase (PARP). Aviculin shows an increase in the Bax/Bcl-2 ratio.
|
-
- HY-P0049A
-
|
Argipressin diacetate
Arg8-vasopressin diacetate; AVP diacetate; ADH
|
Apoptosis
Vasopressin Receptor
|
Neurological Disease
|
|
Argipressin (diacetate) (AVP (diacetate), also known as antidiuretic hormone (ADH)) is a 9 amino acid neuropeptide secreted by the posterior pituitary. Argipressin (diacetate) (AVP (diacetate)) can regulate the biological effects of fluid balance, osmolality and cardiovascular through three separate G-protein coupled receptors (GPCRs), namely Avpr1a (V1a), Avpr1b (V1b) and Avpr2 (V2). Argipressin (diacetate) (AVP (diacetate)) also have potentially important effects on centrally regulated metabolic processes.
|
-
- HY-W018772S15
-
|
D-Ribose(mixture of isomers)-13c5
|
Endogenous Metabolite
|
|
|
D-Ribose(mixture of isomers)- 13C5 isomers)- 13C5 is the 13C labeled D-Ribose(mixture of isomers)[1]. D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner[1].
|
-
- HY-B0601
-
|
Tafluprost acid
AFP-172
|
Prostaglandin Receptor
Drug Metabolite
|
Endocrinology
Neurological Disease
Cardiovascular Disease
|
|
Tafluprost acid (AFP-172), an active metabolic form of Tafluprost, is a selective prostanoid FP receptor agonist. Tafluprost acid shows a high affinity for human prostanoid FP receptor with Ki and EC50 values of 0.4 nM and 0.53 nM, respectively. Tafluprost acid has 126 times weaker binding affinity for prostanoid EP3 receptor (IC50=67 nM) than for the prostanoid FP receptor. Tafluprost acid can be used in the research of glaucoma.
|
-
- HY-Y0698
-
|
Thioacetamide
Acetothioamide; TAA; Thiacetamide
|
Necroptosis
|
Inflammation/Immunology
|
|
Thioacetamide (TAA) is an indirect hepatotoxin and causes parenchymal cell necrosis. Thioacetamide requires metabolic activation by microsomal CYP2E1 to thioacetamide-S-oxide initially and then to thioacetamide-S-dioxide, which is a highly reactive metabolite, and its reactive metabolites covalently bind to proteins and lipids thereby causing oxidative stress and centrilobular necrosis. Thioacetamide can induce chronic liver fibrosis, encephalopathy and other events model.
|
-
- HY-144763
-
|
XPO1-IN-1
|
Apoptosis
|
Cancer
|
|
XPO1-IN-1 (compound D4) is an orally active and potent XPO1 inhibitor, with an IC50 of 24 nM in MM.1S cell. XPO1-IN-1 can efficiently induce cell apoptosis and cell cycle arrest. XPO1-IN-1 displays favorable metabolic stability and pharmacokinetic properties. XPO1-IN-1 can be used for multiple myeloma (MM) research.
|
-
- HY-151200
-
|
Steroid sulfatase-IN-4
|
Others
|
Endocrinology
|
|
Steroid sulfatase-IN-4 (Compound 16) is an irreversible steroid sulfatase (STS) inhibitor with an IC50 of 25 nM against human STS. Steroid sulfatase-IN-4 can be used for the research of endometriosis.
|
-
- HY-127143
-
-
- HY-135236
-
|
OXFBD04
|
Epigenetic Reader Domain
|
Cancer
|
|
OXFBD04 is a potent and selective BRD4 inhibitor with an IC50 of 166 nM. OXFBD04 is a potent BET bromodomain ligand with additional modest affinity for the CREBBP bromodomain. OXFBD04 has anti-cancer activity.
|
-
- HY-145872
-
|
HBV-IN-20
|
HBV
|
Infection
|
|
HBV-IN-20 is a potent and oral active HBV inhibitor with an EC50 of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators).
|
-
- HY-124623
-
|
DNDI-8219
|
Parasite
|
Infection
|
|
DNDI-8219 (compound 58) is a potent selective and orally active trypanocidal agent, possessing inhibitory activity against Trypanosoma cruzi (T.?cruzi) with an IC50 of 0.4 μM. DNDI-8219 has low cytotoxicity (L6 cells IC50 > 100 μM). DNDI-8219 can effectively cure chronic T.?cruzi infection and markedly reduce parasite burdens in mouse model. DNDI-8219 has good solubility, metabolic stability and safety.
|
-
- HY-W356116
-
|
C6 NBD Ceramide
Nbd-ceramide
|
Fluorescent Dye
|
Others
|
|
C6 NBD Ceramide is a Golgi apparatus fluorescent probe with cell membrane permeability. C6 NBD Ceramide can be used for fast and convenient green fluorescent labeling of Golgi in living and fixed cells, and can be used to observe changes in Golgi morphology in living cells (Ex=466 nm, Em=536 nm). C6-NBD-ceramide is metabolized to fluorescent sphingomyelin and glucosylceramide, can be used for the study of sphingolipid transport and metabolic mechanism.
|
-
- HY-151108
-
-
- HY-N6805
-
|
Isoeugenol acetate
Acetyl isoeugenol
|
Cholinesterase (ChE)
|
Cancer
Inflammation/Immunology
|
|
Isoeugenol acetate (Acetyl isoeugenol), an essential oil constituent of nutmeg, clove, and cinnamon, shows excellent inhibitory effects against some metabolic enzymes such as acetylcholinesterase (AChE) enzymes (IC50=77 nM; Ki=16 nM), α-glycosidase (IC50=19.25 nM; Ki=21 nM), and α-amylase (IC50=411.5 nM). Isoeugenol acetate is used medical and cosmetics industries for its antioxidant, anticancer, antimicrobial and anti-inflammatory properties.
|
-
- HY-113439S
-
|
12-HETE-d8
|
Apoptosis
|
Inflammation/Immunology
Cardiovascular Disease
|
|
12-HETE-d8 is the deuterium labeled 12-HETE. 12-HETE, a major metabolic product of arachidonic acid using 12-LOX catalysis, inhibits cell apoptosis in a dose-dependent manner. 12-HETE promotes the activation and nuclear translocation of NF-κB through the integrin-linked kinase (ILK) pathway[1].12-HETE has both anti-thrombotic and pro-thrombotic effects[2]. 12-HETE is a neuromodulator[3].
|
-
- HY-143880
-
|
MRGPRX1 agonist 4
|
Others
|
Neurological Disease
|
|
MRGPRX1 agonist 4 (compound 1t) is a potent and orally active Mas-related G protein-coupled receptor X1 (MRGPRX1) positive allosteric modulator with an EC50 value of 0.1 μM. MRGPRX1 agonist 4 has good metabolic stability and oral bioavailability. MRGPRX1 agonist 4 can reduce behavioral heat hypersensitivity in a neuropathic pain model humanized MRGPRX1 mice. MRGPRX1 agonist 4 can be used for researching neuropathic pain.
|
-
- HY-W127409
-
|
1,2-Dimyristoyl-rac-glycerol
|
Biochemical Assay Reagents
|
Others
|
|
1,2-Dimyristoyl-rac-glycerol (C14:0) is a carboxylic acid ester, glycerolipid and diglyceride with an additional myristoyl group that facilitates interactions between proteins and lipids. Can be used as detergent or reagent. It plays a role in cell biology experiments involving the metabolism and metabolic pathways of glycerolipids. As a diglyceride, this substance consists of two fatty acid chains covalently bonded in the 1,2-form to a glycerol molecule. The diglyceride (DAG) study investigated the process by which DAG is depleted to inhibit fat accumulation. Reagent grade, for research use only.
|
-
- HY-144653
-
|
PDGFR-IN-1
|
PDGFR
Apoptosis
|
Cancer
|
|
PDGFR-IN-1 (compound 7m) is a potent and orally active PDGFR (platelet-derived growth factor receptor) inhibitor, with IC50 values of 2.4 and 0.9 nM for PDGFRα and PDGFRβ, respectively. PDGFR-IN-1 displays robust antitumor effects and low toxicity, and can be used to study osteosarcoma.
|
-
- HY-W271064
-
|
1-Methylpyrene
|
Fluorescent Dye
|
Others
|
|
1-Methylpyrene is a ubiquitous environmental pollutant and rodent carcinogen. Its mutagenic activity depends on sequential activation by various CYP and sulfotransferase (SULT) enzymes. 1-Methylpyrene induces chromosome loss and mitotic disturbance, proba
|
-
- HY-P2161B
-
|
TAK-683 acetate
|
Kisspeptin Receptor
|
Cancer
|
|
TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.
|
-
- HY-P2161A
-
|
TAK-683 TFA
|
Kisspeptin Receptor
|
Cancer
|
|
TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.
|
-
- HY-P2161
-
|
TAK-683
|
Kisspeptin Receptor
|
Cancer
|
|
TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively. TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer.
|
-
- HY-147533
-
-
- HY-147908
-
|
Adenosine receptor inhibitor 2
|
Adenosine Receptor
|
Inflammation/Immunology
|
|
Adenosine receptor inhibitor 2 (compound 14b) is a potent AR (adenosine receptor) inhibitor. Adenosine receptor inhibitor 2 shows dual affinity toward A1/A2A ARs with higher affinity for the A1- than the A2AAR. Adenosine receptor inhibitor 2 has Ki values of 52.2 nM for the A1AR and 167 nM for the A2AAR.
|
-
- HY-126291
-
|
GNE-616
|
Sodium Channel
|
Neurological Disease
|
|
GNE-616 is a highly potent, metabolically stable, orally bioavailable, and subtype selective Nav1.7 inhibitor (Ki of 0.79 nM and Kd of 0.38 nM for hNav1.7) for the treatment of chronic pain. GNE-616 shows >1000 nM Kd and >2500-fold selectivity over hNav1.1, hNav1.3, hNav1.4, and hNav1.5. Selectivity over hNav1.2 and hNav1.6 is more modest at 31- and 73-fold, respectively.
|
-
- HY-147319
-
|
RTI-7470-44
|
Others
|
Neurological Disease
|
|
RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant human trace amine-associated receptor subtype 1 (hTAAR1) antagonist with an IC50 value of 8.4 nM and a Ki value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD).
|
-
- HY-N10519
-
|
Cellooctaose
|
Others
|
Others
|
|
Cellooctaose is an oligosaccharide, consisting of eight glucose residues. Cellooctaose is a low-cost polysaccharides in fermentation to hold on Lactococcus lactis recombinant strain growth. Cellooctaose is the substrate of beta-glucosidase (E.C. 3.2.1.21).
|
-
- HY-149916
-
|
A2AR-antagonist-1
|
Adenosine Receptor
|
Cancer
|
|
A2AR-antagonist-1 (compound 38) is an orally active adenosine A2A receptor (A2AR) antagonist (IC50=29 nM). A2AR-antagonist-1 exhibits anti-tumor activity and mouse liver microsomal metabolic stability (t1/2=86.1 min). A2AR-antagonist-1 is also a T cells activator, via inhibiting immunosuppressive molecules (LAG-3 and TIM-3) and enhancing effector molecules (GZMB, IFNG, and IL-2).
|
-
- HY-14393S
-
|
Emodin-d4
Frangula emodin-d4
|
Isotope-Labeled Compounds
SARS-CoV
Casein Kinase
Autophagy
11β-HSD
|
Cancer
|
|
Emodin-d4 is the deuterium labeled Emodin. Emodin (Frangula emodin), an anthraquinone derivative, is an anti-SARS-CoV compound. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 (ACE2) interaction[1]. Emodin inhibits casein kinase-2 (CK2). Anti-inflammatory and anticancer effects[2]. Emodin is a potent selective 11β-HSD1 inhibitor with the IC50 of 186 and 86 nM for human and mouse 11β-HSD1, respectively. Emodin ameliorates metabolic disorder in diet-induced obese mice[3].
|
-
- HY-14280S
-
|
Entacapone-d10
|
COMT
|
Neurological Disease
|
|
Entacapone-d10 is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].
|
-
- HY-14280S2
-
|
(E)-Entacapone-d10
|
COMT
|
Neurological Disease
|
|
(E)-Entacapone-d10 is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease[1]. Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders[2].
|
-
- HY-146201
-
|
PDE4B/7A-IN-1
|
Phosphodiesterase (PDE)
|
Others
|
|
1 a /5-hydroxynitrile rubber 7 receptor antagonist (5-HT1 a k i = 8 nm, kb= 0.04 nm; 5-nitrile rubber 7K I = 451 nm, kb= 460 nm) has pde4b/pde7a inhibitory activity (PDE4B ic50= 80.4 μ M; Pde7a chip 50= 151.3 μ M）。 Compound 22 has a very good ability of passive penetration of biofilm and high metabolic stability in vitro. In addition, 22's pharmacological evaluation showed its pre cognitive and antidepressant properties in rat behavioral tests.
|
-
- HY-16750
-
|
Radalbuvir
GS-9669
|
HCV
|
Infection
|
|
Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC50 = 2.9 nM, GT1b EC50 = 6 nM).
|
-
- HY-136241
-
|
OT-82
|
NAMPT
Caspase
|
Cancer
|
|
OT-82 is a potent, selective and orally active inhibitor of NAMPT. OT-82 is selectively toxic to cells of hematopoietic origin and induces cell death in a NAD + dependent manner. OT-82 is a promising antineoplastic agent for the study of hematological malignancies.
|
-
- HY-151096
-
|
ACT-660602
|
CXCR
|
Inflammation/Immunology
|
|
ACT-660602 is an orally active antagonist of chemokine receptor (CXCR3) with an IC50 value of 204 nM. ACT-660602 inhibits T-cell migration and shows efficacy in acute lung ingury model. ACT-660602 can be used for autoimmune diseases research.
|
-
- HY-W251428
-
|
Phosphatidylglycerols (egg) (sodium salt)
|
Biochemical Assay Reagents
|
Others
|
|
Phosphatidylglycerol is a naturally occurring anionic phospholipid that is a component of plant, animal and bacterial cell membranes. It is present in prokaryotes and eukaryotes less than phosphatidylethanolamine, and in eukaryotes less than phosphatidylcholine. It is formed by the reaction between CDP-diglyceride and L-α-glycerol 3-phosphate followed by dephosphorylation and is the metabolic precursor of cardiolipin. Phosphatidylglycerols containing polyunsaturated and monounsaturated fatty acyl chains inhibit and promote the proliferation of murine keratinocytes, respectively. Phosphatidylglycerol is the second-largest lipid component of mammalian lung surfactant, accounting for 10% of lipids, and has reduced levels of pulmonary surfactant in infants with respiratory distress syndrome. Phosphatidylglycerol (egg) is a mixture of phosphatidylglycerols isolated from eggs with various fatty acyl groups at the sn-1 and sn-2 positions. References: [1]. Ohtsuka, T., Nishijima, M., and Akamatsu, Y. Phosphatidylglycerol phosphate synthase-deficient somatic mutants with impaired phosphatidylglycerol and cardiolipin biosynthesis J. Biol. Chemical. 268(30), 22908-22913 (1993).[2]. Furse, S. Are phosphatidylglycerols essential for terrestrial life? J. Chemistry. biology. 10(1), 1-9 (2016).[3]. Xie, D., Seremwe, M., Edwards, JG, et al. Different effects of different phosphatidylglycerols on the proliferation of mouse keratinocytes PLoS One 9(9), e107119 (2014).
|
-
- HY-126986
-
-
- HY-101457
-
|
JZP-430
|
MAGL
|
Metabolic Disease
|
|
JZP-430 is a potent, highly selective, irreversible inhibitor of α/β-hydrolase domain 6 (ABHD6) with an IC50 of 44 nM, exhibits ~230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL).
|
-
- HY-109030
-
-
- HY-N2362S1
-
|
DL-Alanine-13C-3
DL-2-Aminopropionic acid-13C-3
|
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-Alanine- 13C-3 is the 13C-labeled DL-Alanine. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver[1][2][3][4][5][6].
|
-
- HY-B2192
-
|
Amylase
|
Others
|
Metabolic Disease
|
|
Amylase is an enzyme produced by pancreas and salivary glands, catalyzing the hydrolysis of starch into sugars. Amylase are broadly classified into α, β, and γ subtypes.
|
-
- HY-117771
-
|
DO34
|
Others
|
Metabolic Disease
|
|
DO34 is a highly potent, selective and centrally active diacylglycerol lipase (DAGL) inhibitor, with an IC50 of 6 nM for DAGLα conversion of SAG to 2-AG, and an IC50 for DAGLβ.
|
-
- HY-W013179
-
-
- HY-129630S
-
|
Tetrahydrocortisol-d5
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Tetrahydrocortisol-d5 is the deuterium labeled Tetrahydrocortisol. Tetrahydrocortisol is cortisol metabolite. The urinary Tetrahydrocortisol/Tetrahydrocortisone ratio decreases with increasing 11β-hydroxysteroid dehydrogenase (11β-HSD) activity[1][2].
|
-
- HY-N10594
-
-
- HY-12357
-
-
- HY-N3431
-
-
- HY-106373A
-
-
- HY-N7021
-
-
- HY-144713
-
|
PTP1B-IN-16
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-16 (Compound 46), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 12.6 μM. PTP1B-IN-16 can be used for the research of type 2 diabetes.
|
-
- HY-W127369
-
-
- HY-113248S1
-
-
- HY-P3260
-
-
- HY-114456
-
|
Ganglioside GM3
|
Others
|
Metabolic Disease
|
|
Ganglioside GM3 is a precursor of a-, b-, and c-series gangliosides, interacts with transmembrane receptors such as the epidermal growth factor and insulin receptors, and regulates receptor functions by creating a specialized lipid environment. Ganglioside GM3 is synthesized by GM3 synthase and can be used for the research of hypercholesterolemia.
|
-
- HY-W001117
-
-
- HY-15193B
-
-
- HY-N7347
-
|
(-)-Hydroxycitric acid lactone
Garcinia lactone
|
ATP Citrate Lyase
|
Metabolic Disease
|
|
(-)-Hydroxycitric acid lactone (Garcinia lactone) is an anti-obesity agent and a popular weight loss food supplement. (-)-Hydroxycitric acid lactone is a potent inhibitor of ATP-citrate lyase. (-)-Hydroxycitric acid lactone catalyzes the extramitochondrial cleavage of citrate to oxaloacetate and acetyl-CoA, limits the availability of acetyl-CoA units required for fatty acid synthesis.
|
-
- HY-126410
-
|
Petunidin chloride
|
FAK
|
Metabolic Disease
|
|
Petunidin chloride is an O-methylated anthocyanidin derived from delphinidin. Petunidin chloride binds with and suppresses the activity of focal adhesion kinase and to inhibit platelet-derived growth factor-induced aortic smooth muscle cell migration, which may confer a protective effect against atherosclerosis.
|
-
- HY-128344
-
|
BR102375
|
PARP
Apoptosis
|
Metabolic Disease
|
|
BR102375 is a non-TZD peroxisome proliferator-activated receptor γ (PPAR γ) full agonist for the treatment of type 2 diabetes, reveals EC50 value of 0.28 μM and Amax ratio of 98%.
|
-
- HY-133033
-
|
COQ7-IN-1
|
Others
|
Metabolic Disease
|
|
COQ7-IN-1, a highly potent inhibitor of human coenzyme Q (COQ7), interferes with ubiquinone (UQ) synthesis. COQ7-IN-1 does not disturb physiological cell growth of human normal culture cells. COQ7-IN-1 can be used for the research of the balance between UQ supplementation pathways: de novo UQ synthesis and extracellular UQ uptake.
|
-
- HY-50290A
-
-
- HY-112860
-
-
- HY-100181
-
-
- HY-W013078S
-
-
- HY-W030796A
-
|
Lactisole
|
Others
|
Metabolic Disease
|
|
Lactisole is a canonical antagonist of sweet taste receptor, selectively targeting to T1R3 subunit, a glucose-sensing receptor. Lactisole inhibits insulin secretion induced by glucose in mouse islets.
|
-
- HY-B0224A
-
-
- HY-W006429
-
|
L-Uridine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Uridine, isolated from the Polyporaceae fungus Poria cocos (Schw.), is an enantiomer of the normal RNA constituent D-uridine. L-uridine acts as a phosphate acceptor for nucleoside phosphotransferases.
|
-
- HY-151578
-
|
DPP IV/hCA II-IN-1
|
Dipeptidyl Peptidase
Carbonic Anhydrase
|
Metabolic Disease
|
|
DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) inhibitor with an IC50 value of 0.049 μM for DPP IV and with Ki values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively.
|
-
- HY-113451
-
-
- HY-N0215S
-
|
L-Phenylalanine-d7
(S)-2-Amino-3-phenylpropionic acid-d7
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine-d7 is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-145381
-
|
11β-HSD1-IN-6
|
11β-HSD
|
Metabolic Disease
|
|
11β-HSD1-IN-6 is a an 11β-HSD-1 inhibitor. The 11β hydroxysteroid dehydrogenase enzymes (11β-HSDs) mediate the interconversion of the glucocorticoid (GC) corticosterone or cortisol to an inactive form, 11-dehydrocorticosterone (11-DHC) or Cortisone, respectively.
|
-
- HY-Y0078
-
-
- HY-B0283A
-
|
Acipimox sodium
K-9321 sodium
|
Others
|
Metabolic Disease
|
|
Acipimox (K-9321) sodium, a nicotinic acid analogue, is an antilipolytic compound. Acipimox sodium stimulates leptin releas, inhibits lipolysis and suppresses systemic levels of free fatty acids (FFAs) and improves insulin sensitivity.
|
-
- HY-15330
-
-
- HY-N0623S2
-
-
- HY-P99359
-
|
Elezanumab
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism.
|
-
- HY-W040256
-
-
- HY-128742
-
-
- HY-41417S3
-
|
Octanoic acid-13C
Caprylic acid-13C
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Octanoic acid- 13C is the 13C labeled Octanoic acid. Octanoic acid (Caprylic acid) is an oily liquid with a slightly unpleasant rancid taste and used commercially in the production of esters used in perfumery and also in the manufacture of dyes.
|
-
- HY-142643
-
-
- HY-113076S
-
-
- HY-130705
-
-
- HY-19884B
-
|
Relamorelin TFA
RM-131 TFA; BIM-28131 TFA
|
GHSR
|
Metabolic Disease
|
|
Relamorelin (RM-131) TFA, a pentapeptide ghrelin analog, is a selective ghrelin/growth hormone secretagogue receptor (GHSR) agonist with a Ki of 0.42 nM for GHS-1a receptor. Relamorelin TFA is centrally penetrant. Relamorelin TFA increases growth hormone levels and accelerates gastric emptying. Relamorelin TFA has the potential for cachexia, gastroparesis, and gastric/intestinal dysmobility disorders research.
|
-
- HY-N6858
-
|
4-Hydroxyisoleucine
4-Hydroxy-L-isoleucine
|
Others
|
Metabolic Disease
|
|
4-Hydroxyisoleucine (4-Hydroxy-L-isoleucine) is an amino acid which can be extracted and purified from fenugreek seeds. 4-Hydroxyisoleucine (4-Hydroxy-L-isoleucine) displays an insulinotropic activity of great interest.
|
-
- HY-129683
-
|
AM3102
|
PPAR
|
Metabolic Disease
|
|
AM3102 is an oleoylethanolamide (OEA) analog. AM3102 is an endogenous high-affinity PPAR-alpha agonist. AM3102 resists enzymatic hydrolysis, activates PPAR-alpha with high potency in vitro, and persistently reduces feeding when administered in vivo either parenterally or orally.
|
-
- HY-125671
-
-
- HY-W013495S
-
-
- HY-N11454
-
-
- HY-119395A
-
-
- HY-W010452S1
-
-
- HY-105185
-
|
Fidarestat
SNK 860
|
Aldose Reductase
|
Metabolic Disease
|
|
Fidarestat (SNK 860) is an inhibitor of aldose reductase, with IC50s of 26 nM, 33 μM, and 1.8 μM for aldose reductase, AKR1B10 and V301L AKR1B10, respectively; Fidarestat (SNK 860) has the potential to treat diabetic disease.
|
-
- HY-W004066
-
-
- HY-W015213
-
-
- HY-146453
-
-
- HY-W018501
-
-
- HY-N0224A
-
|
Goitrin
(S)-Goitrin; L-5-Vinyl-2-thiooxazolidone
|
Influenza Virus
|
Metabolic Disease
|
|
Goitrin ((S)-Goitrin), a product of glucosinolate-myrosinase reactions, is a potent inhibitor of thyroid peroxidase. Goitrin can inhibit iodine utilization by the thyroid. Goitrin also exhibits anti-influenza virus (H1N1) activity.
|
-
- HY-Y0444
-
|
D-Tyrosine
|
Tyrosinase
|
Metabolic Disease
|
|
D-Tyrosine is the D-isomer of tyrosine. D-Tyrosine negatively regulates melanin synthesis by inhibiting tyrosinase activity. D-Tyrosine inhibits biofilm formation and trigger the self-dispersal of biofilms without suppressing bacterial growth.
|
-
- HY-N6022
-
|
Byakangelicin
|
Others
|
Metabolic Disease
|
|
Byakangelicin, one of the active compounds found in the roots of Angelica gigas, can serve as a modulator to improve brain accumulation of diverse active compounds (Umb, Cur, and Dox) and enhance therapeutic effects. Byakangelicin is likely to increase the expression of all PXR target genes (such as MDR1) and induce a wide range of agent-agent interactions. Byakangelicin can inhibit the effects of sex hormones, it may increase the catabolism of endogenous hormones.
|
-
- HY-14854A
-
|
Tecarfarin sodium
ATI-5923 sodium
|
Others
|
Metabolic Disease
|
|
Tecarfarin sodium (ATI-5923 sodium) is a novel orally active non-competitive vitamin K epoxide reductase (VKOR) antagonist, impairs the activation of the vitamin K-dependent clotting factors II, VII, IX and X.
Tecarfarin sodium has the antithrombotic activity.
|
-
- HY-N11477
-
|
(2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid
|
Glucosidase
|
Metabolic Disease
|
|
(2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid is a saponin that can be isolated from Rubus ellipticus var. obcordatus. (2α,3β,4α)-2,3,19-Trihydroxyurs-12-ene-23,28-dioic acid inhibits α-Glucosidase with an IC50 of 1.68 mM.
|
-
- HY-124346
-
|
T-3364366
|
Others
|
Metabolic Disease
|
|
T-3364366 is a reversible, slow-binding, thienopyrimidinone delta-5 desaturase (D5D) inhibitor with IC50s of 1.9 nM and 2.1 nM in HepG2 and RLN-10 cells, respectively. T-3364366 exhibits potent D5D (IC500=19 nM) inhibitory activity and excellent selectivity away from delta-6 desaturase (D6D, IC50=6200 nM) and delta-9 desaturase (stearoyl-CoA desaturase, SCD,50 >10000 nM) in the enzymatic activity assay.
|
-
- HY-144033
-
|
GLP-1R agonist 1
|
GCGR
|
Metabolic Disease
|
|
GLP-1R agonist 1 is a potent agonist of GLP-1R. GLP-1R agonist 1 is a thickened imidazole derivative compound. Glucagon-like peptide-1 (GLP-1) is an intestinal hypoglycemic hormone secreted by L-cells in the lower gastrointestinal tract. GLP-1R agonist 1 has the potential for the research of diabetes (extracted from patent WO2021197464A1, compound 4).
|
-
- HY-144456
-
|
Xanthine oxidase-IN-5
|
Xanthine Oxidase
|
Metabolic Disease
|
|
Xanthine oxidase-IN-5 is an effective and orally active xanthine oxidase (XO) inhibitor with IC50 value of 0.70 μM. Xanthine oxidase-IN-5 displays favorable agent-like properties with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 shows potent hypouricemic effects in hyperuricemic rat model.
|
-
- HY-N2616
-
-
- HY-Y0504S4
-
-
- HY-N2221
-
-
- HY-N0468
-
-
- HY-N2109
-
|
Macranthoidin A
|
Others
|
Metabolic Disease
|
|
Macranthoidin A is an orally active saponin from Flos Lonicerae. Macranthoidin A possess protection effects on hepatic injury caused by Acetaminophen, Cd, and CCl4, and conspicuous depressant effects on swelling of ear croton oil.
|
-
- HY-N7433
-
-
- HY-W013061
-
-
- HY-151142
-
-
- HY-144509S
-
-
- HY-W016562S3
-
|
Hippuric acid-15N
2-Benzamidoacetic acid-15N
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Hippuric acid- 15N is the 15N-labeled Hippuric acid. Hippuric Acid (2-Benzamidoacetic acid), an acyl glycine produced by the conjugation of benzoic acid and glycine, is a normal component in urine as a metabolite of aromatic compounds from food.
|
-
- HY-Y1173
-
-
- HY-P2231
-
|
Cotadutide
MEDI0382
|
GCGR
|
Metabolic Disease
|
|
Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D).
|
-
- HY-N4107
-
|
Phyllanthin
|
Others
|
Metabolic Disease
|
|
Phyllanthin is a major bioactive lignan component of Phyllanthus amarus. Phyllanthin exhibits high antioxidative and hepatoprotective properties.
|
-
- HY-Y0337
-
|
L-Cysteine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Cysteine is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine suppresses ghrelin and reduces appetite in rodents and humans.
|
-
- HY-128895
-
|
KL1333
|
Mitochondrial Metabolism
|
Metabolic Disease
|
|
KL1333, a derivative of β-lapachone, is an orally available NAD+ modulator. KL1333 reacts with NAD(P)H:quinone oxidoreductase 1 (NQO1) as a substrate, resulting in increases in intracellular NAD+ levels via NADH oxidation. KL1333 improves energy metabolism and mitochondrial dysfunction in MELAS fibroblasts. KL1333 protects against Cisplatin-induced ototoxicity in mouse cochlear cultures.
|
-
- HY-100120
-
-
- HY-N4313
-
-
- HY-114855
-
|
BT2
|
Bcl-2 Family
|
Metabolic Disease
|
|
BT2 is a BCKDC kinase (BDK) inhibitor with an IC50 of 3.19 μM. BT2 binding to BDK triggers helix movements in the N-terminal domain, resulting in the dissociation of BDK from the branched-chain α-ketoacid dehydrogenase complex (BCKDC). BT2 (compound 4) is also a potent and selective Mcl-1 inhibitor with a Ki value of 59 μM.
|
-
- HY-W040088
-
-
- HY-110083
-
-
- HY-10871A
-
-
- HY-B0664S
-
|
Ciprofibrate D6
|
PPAR
|
Metabolic Disease
|
|
Ciprofibrate-d6 is deuterium labeled Ciprofibrate. Ciprofibrate (Win35833) is a potent peroxisome proliferator, increases the phosphorylation level of the PPARalpha[1].
|
-
- HY-N4334
-
-
- HY-128487
-
|
H-Trp-Glu-OH
G3335
|
PPAR
|
Metabolic Disease
|
|
H-Trp-Glu-OH is a selective, reversible and cell-permeable PPARγ with a Kd of ~8 µM. H-Trp-Glu-OH might be developed as a possible lead compound in diabetes research.
|
-
- HY-100333
-
-
- HY-20558
-
-
- HY-W016715
-
|
L-Cysteine hydrochloride hydrate
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Cysteine hydrochloride hydrate is a conditionally essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione and taurine. L-Cysteine hydrochloride hydrate suppresses ghrelin and reduces appetite in rodents and humans.
|
-
- HY-W017613
-
-
- HY-Y0289
-
-
- HY-135024
-
|
Phenylacetyl CoA
Phenylacetyl Coenzyme A
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Phenylacetyl CoA is an acceptor oxidoreductase. Phenylacetyl CoA is a membrane-bound molybdenum–iron–sulfur enzyme involved in anaerobic metabolism of phenylalanine in the denitrifying bacterium Thauera aromatica.
|
-
- HY-P3495
-
-
- HY-114365
-
|
UDP-GalNAc disodium
UDP-N-acetyl-D-galactosamine disodium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
UDP-GalNAc (UDP-N-acetyl-D-galactosamine) disodium is a sugar nucleotide and a substrate of EpsC115. EpsC115 is an exopolymeric substances (EPS) N-terminal deletion mutant with the residue 1-115 deletion. UDP-GalNAc UDP-GalNAc is the donor substrate of many N-acetylgalactosaminyltransferases, enzymes which transfer GalNAc from the nucleotide sugar to a saccharide or peptide acceptor.
|
-
- HY-101076
-
|
L-690488
|
Phosphatase
|
Metabolic Disease
|
|
L-690488 is a proagent of L-690330 and is a selective inositol monophosphatase (IMPase) inhibitor. L-690488 has more effective cell penetration than L-690330.
|
-
- HY-W014901
-
-
- HY-128743
-
-
- HY-P1366
-
|
des-Gln14-Ghrelin
|
GHSR
|
Metabolic Disease
|
|
des-Gln14-Ghrelin is a second endogenous ligand for the growth hormone secretagogue receptor. a). des-Gln14-ghrelin potently induces increases in [Ca 2+]i in CHO-GHSR62 cells, with an EC50 of 2.4 nM.
|
-
- HY-113206
-
-
- HY-Y1009S
-
-
- HY-N9397
-
-
- HY-A0132S10
-
-
- HY-129658
-
|
TT-OAD2 free base
|
GCGR
|
Metabolic Disease
|
|
TT-OAD2 free base is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 free base has the potential for diabetes treatment.
|
-
- HY-W015913S4
-
-
- HY-128374
-
-
- HY-19908
-
-
- HY-N0384S1
-
|
Homovanillic acid-d2
Vanilacetic acid-d2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Homovanillic acid-d2 is the deuterium labeled Homovanillic acid. Homovanillic acid is a dopamine metabolite found to be associated with aromatic L-amino acid decarboxylase deficiency, celiac disease, growth hormone deficiency, and sepiapterin reductase deficiency.
|
-
- HY-111961
-
-
- HY-W008820S2
-
|
Glutaric acid-d2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glutaric acid-d2 is the deuterium labeled Glutaric acid. Glutaric acid, C5 dicarboxylic acid, is an intermediate during the catabolic pathways of lysine and tryptophan. Glutaric acid affects pericyte contractility and migration. Glutaric acid is an indicator of glutaric aciduria type I[1][2][3].
|
-
- HY-113432
-
-
- HY-W014787S1
-
|
Decanedioic acid-d16
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Decanedioic acid-d16 is the deuterium labeled Decanedioic acid[1]. Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency[2].
|
-
- HY-14657
-
-
- HY-128753S7
-
-
- HY-145542
-
-
- HY-108341
-
|
PF-06424439
|
Acyltransferase
|
Metabolic Disease
|
|
PF-06424439 is an oral, potent and selective imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitor with an IC50 of 14 nM. PF-06424439 is slowly reversible, time-dependent inhibitor, which inhibits DGAT2 in a noncompetitive mode with respect to the acyl-CoA substrate.
|
-
- HY-P1070A
-
|
Amylin, amide, human TFA
DAP amide, human TFA
|
Amylin Receptor
|
Metabolic Disease
|
|
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent.
|
-
- HY-139467
-
|
PF-04577806
|
SHP2
PKC
|
Metabolic Disease
|
|
PF-04577806 is a potent, selective and ATP competitive PKC inhibitor. PF-04577806 shows potent inhibitory activity towards PKCα, PKCβI, PKCβII, PKCγ, and PKCθ with IC50s of 2.4 nM, 8.1 nM, 6.9 nM, 45.9 nM, and 29.5 nM, respectively. PF-04577806 can reverse retinal vascular leakage in diabetic rats.
|
-
- HY-13967B
-
|
AMG 837 calcium hydrate
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 calcium hydrate inhibits specific [ 3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 calcium hydrate could enhance insulin secretion and lower glucose levels in rodents.
|
-
- HY-N2003
-
|
D-Tetrahydropalmatine
|
Dopamine Receptor
|
Metabolic Disease
|
|
D-Tetrahydropalmatine is an isoquinoline alkaloid, mainly in the genus Corydalis. D-Tetrahydropalmatine is a dopamine (DA) receptor antagonist with preferential affinity toward the D1 receptors. D-Tetrahydropalmatine is a potent organic cation transporter 1 (OCT1) inhibitor.
|
-
- HY-145086
-
|
R-PSOP
|
Others
|
Metabolic Disease
|
|
R-PSOP is highly potent and selective nonpeptidic NMUR2 antagonist. R-PSOP binds to NMUR2 with the Kis of 52 and 32 nM for the human and rat NMUR2, respectively. R-PSOP shows moderate CNS penetration. R-PSOP can be used for the research of the eating disorders, obesity, pain, and stress-related disorders.
|
-
- HY-143692
-
|
SQDG
|
Liposome
|
Metabolic Disease
|
|
SQDG is a glycolipid that possesses sugar moieties in their head groups. SQDG is a membrane lipid that can be used to investigate the effects of structural lipid in LNP formulations.
|
-
- HY-N0455B
-
|
L-Arginine (L-glutamate)
(S)-(+)-Arginine (L-glutamate)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Arginine L-glutamate ((S)-(+)-Arginine L-glutamate) is the nitrogen donor for synthesis of nitric oxide. L-Arginine L-glutamate can be used for upper gastrointestinal hypofunction or dysfunction like functional dyspepsia research.
|
-
- HY-128749
-
-
- HY-P1430A
-
-
- HY-147678
-
|
GPR40 agonist 5
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice.
|
-
- HY-N0215S1
-
|
L-Phenylalanine-d8
(S)-2-Amino-3-phenylpropionic acid-d8
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine-d8 is the deuterium labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-112598A
-
|
PF-06815345 hydrochloride
|
Ser/Thr Protease
|
Metabolic Disease
|
|
PF-06815345 hydrochloride is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 hydrochloride significantly decreases the PCSK9 level in vivo in mouse.
|
-
- HY-B0445S
-
-
- HY-148575
-
|
α-Glucosidase-IN-23
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC50 value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes.
|
-
- HY-109542
-
|
Cyclopenthiazide
|
Others
|
Metabolic Disease
|
|
Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney.
|
-
- HY-30004
-
-
- HY-145678
-
-
- HY-W010452S2
-
-
- HY-126488
-
-
- HY-135298
-
-
- HY-137083
-
|
Trifluoperazine N-Glucuronide
UGT1A4
|
Others
|
Metabolic Disease
|
|
Trifluoperazine N-Glucuronide (UGT1A4), as one of the human UGT1A isoforms, is expressed in the liver. Trifluoperazine N-Glucuronide catalyzes the imipramine and trifluoperazine Nglucuronide formation.
|
-
- HY-12590
-
-
- HY-108711
-
-
- HY-N7098
-
-
- HY-113068
-
|
(rel)-β-Tocopherol
|
Tyrosinase
|
Metabolic Disease
|
|
(rel)-β-Tocopherol is a relative configuration of β-Tocopherol.(±)-β-Tocopherol is a lipid-soluble form of vitamin E with antioxidant activity. β-Tocopherol can inhibit tyrosinase activity and melanin synthesis. β-Tocopherol also can prevent the inhibition of cell growth and of PKC activity caused by d-alpha-tocopherol.
|
-
- HY-W019151S
-
-
- HY-137061
-
-
- HY-116263
-
-
- HY-B0089
-
|
Acarbose
BAY g 5421
|
Glucosidase
|
Metabolic Disease
|
|
Acarbose (BAY g 5421), antihyperglycemic agent, is an orally active alpha-glucosidase inhibitor (IC50=11 nM). Acarbose can potentiate the hypoglycemic effects of sulfonylureas or insulin.
|
-
- HY-N8243
-
|
Coreopsin
|
Others
|
Metabolic Disease
|
|
Coreopsin is a natural product that can be isolated from Coreopsis tinctoria Nutt. flower. Coreopsin can be used for hypertension and diabetes research.
|
-
- HY-125783S2
-
-
- HY-W049735
-
-
- HY-113527
-
-
- HY-15340
-
|
LG100268
LG268
|
RAR/RXR
Autophagy
|
Metabolic Disease
|
|
LG100268 (LG268) is a potent, selective and orally active retinoid X receptor (RXR) agonist with EC50 values of 4 nM, 3 nM, and 4 nM for RXR-α, RXR-β, and RXR-γ, respectively. LG100268 displays >1000-fold selectivity for RXR over RAR, the Ki values are 3.4 nM, 6.2 nM and 9.2 nM for RXR-α, RXR-β, and RXR-γ, respectively. LG100268 activates RXR homodimers to induce transcriptional activation. LG100268 can be used for the study of lung carcinogenesisy.
|
-
- HY-108523
-
|
LG100754
UVI 2112
|
RAR/RXR
|
Metabolic Disease
|
|
LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR.
|
-
- HY-B0511S1
-
-
- HY-113079
-
-
- HY-U00200
-
-
- HY-138620
-
-
- HY-19835
-
|
LY2922470
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
LY2922470 is a potent, selective and orally available agonist of the G protein-coupled receptor 40 (GPR40), with EC50s of 7 nM, 1 nM and 3 nM for human GPR40, mouse GPR40 and rat GPR40, respectively. LY2922470 reduces glucose levels along with significant increases in insulin and GLP-1, is potential for the treatment of type 2 diabetes mellitus (T2DM).
|
-
- HY-N0341
-
|
Scopolin
|
Sirtuin
|
Metabolic Disease
|
|
Scopolin is a coumarin isolated from Arabidopsis thaliana (Arabidopsis) roots. Scopolin attenuated hepatic steatosis through activation of SIRT1-mediated signaling cascades.
|
-
- HY-B0866
-
|
Ametryn
|
Others
|
Metabolic Disease
|
Ametryn, a member of the Triazine chemical family, is a herbicide which inhibits photosynthesis and other enzymatic processes. Ametryn is effective against annual broadleaf weeds and grasses.
|
-
- HY-B2236S
-
|
DL-Lysine-4,4,5,5-d4 dihydrochloride
(±)-2,6-Diaminocaproic acid-4,4,5,5-d4 (dihydrochloride)
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
DL-Lysine-4,4,5,5-d4 (dihydrochloride) is the deuterium labeled DL-Lysine. DL-Lysine is a racemic mixture of the D-Lysine and L-Lysine. Lysine is an α-amino acid that is used in the biosynthesis of proteins[1].
|
-
- HY-101064S1
-
|
Fmoc-leucine-13C6,15N
|
PPAR
|
Metabolic Disease
|
|
Fmoc-leucine- 13C6, 15N is a 15N-labeled and 13C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity
|
-
- HY-135772
-
-
- HY-113308AS
-
-
- HY-W014930
-
-
- HY-P2756
-
-
- HY-U00242
-
|
Indacrinone
MK-196; Indacrynic acid
|
Others
|
Metabolic Disease
|
|
Indacrinone (MK196) is an investigational diuretic which has pronounced saluretic activity in the rat and dog as well as both uricosuric and saluretic activity in the chimpanzee.
|
-
- HY-112942A
-
|
CMP-Sialic acid sodium salt
CMP-Neu5Ac sodium salt
|
Endogenous Metabolite
|
Metabolic Disease
|
|
CMP-Sialic acid (CMP-Neu5Ac) sodium salt is an allosteric inhibitor of UDP-GlcNAc 2-epimerase. CMP-Sialic acid sodium salt provides a substrate for Golgi sialyltransferases. CMP-Sialic acid sodium salt is an important sugar nucleotide for biosynthesis of sialic acid and its conjugates.
|
-
- HY-125265
-
-
- HY-139381
-
|
MitoEbselen-2 chloride
MitoPeroxidase 2
|
Apoptosis
|
Metabolic Disease
|
|
MitoEbselen-2 chloride (MitoPeroxidase 2), a mitochondria-targeted mimic of glutathione peroxidase, is a radiation mitigator. MitoEbselen-2 chloride is effective in reducing lipid hydroperoxides, preventing apoptotic cell death.
|
-
- HY-135955
-
-
- HY-N2155
-
-
- HY-147964
-
-
- HY-137093
-
-
- HY-N2093
-
|
Vicine
|
Others
|
Metabolic Disease
|
|
Vicine, an alkaloid glycoside found mainly in fava beans, is toxic in individuals and may cause haemolytic anaemia.
|
-
- HY-N1411
-
|
Platycodin D
|
AMPK
Wnt
|
Metabolic Disease
|
|
Platycodin D is a saponin isolated from Platycodon grandiflorus, acts as an activator of AMPKα, with anti-obesity property. WNT/β-catenin pathway mediates the anti-adipogenic effect of platycodin D.
|
-
- HY-D1053
-
-
- HY-50675
-
|
GRA Ex-25
|
GCGR
|
Metabolic Disease
|
|
GRA Ex-25 is an inhibitor of glucagon receptor, with IC50 of 56 and 55 nM for rat and human glucagon receptors, respectively.
|
-
- HY-103352
-
|
L-006235
L-235
|
Cathepsin
|
Metabolic Disease
|
|
L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC50 of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (Ki=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (Ki=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss.
|
-
- HY-N3413
-
|
Kushenol X
|
Others
|
Metabolic Disease
|
|
Kushenol X, a flavonoid compound isolated from the roots of Sophora flavescens. Kushenol X is a potent β-glucuronidase and human carboxylesterase 2 (hCE2) inhibitor with IC50s of 2.07 μM and 3.05 μM, respectively.
|
-
- HY-131648
-
|
1-Oleoyl-2-acetyl-sn-glycerol
|
PKC
|
Metabolic Disease
|
|
1-Oleoyl-2-acetyl-sn glycerol is a synthetic, cell permeable diacylglycerol analog. 1-Oleoyl-2-acetyl-sn glycerol activates calcium-dependent protein kinase C (PKC) and induces the superoxide-production.
|
-
- HY-B1476
-
-
- HY-P1714
-
|
Apraglutide
FE 203799
|
GLP Receptor
|
Metabolic Disease
|
|
Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum.
|
-
- HY-N0339
-
-
- HY-15671A
-
|
GKA50 quarterhydrate
|
Glucokinase
|
Metabolic Disease
|
|
GKA50 quarterhydrate is a potent glucokinase activator (EC50=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca 2+-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats.
|
-
- HY-70005
-
-
- HY-138068
-
-
- HY-W096159
-
|
D-Biotinol
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Biotinol is the nutrition of Lactobacillus arabinosus, L. casei, or Saccharomyces cerevisiae. D-Biotinol replaces the D-biotin (HY-B0511) in saving egg white induced biotin deficiency in rats. D-Biotinol is orally active and displays to be converted to biotin by rats.
|
-
- HY-W008452S
-
|
H-Tyr(3-I)-OH-13C6
|
Endogenous Metabolite
|
Metabolic Disease
|
|
H-Tyr(3-I)-OH- 13C6 is the 13C-labeled H-Tyr(3-I)-OH. H-Tyr(3-I)-OH is a potent and effective tyrosine hydroxylase inhibitor. H-Tyr(3-I)-OH is an intermediate in the production of thyroid hormones and has a role as a human or mouse metabolite[1][2].
|
-
- HY-Y0504S
-
-
- HY-W013706
-
-
- HY-12689
-
|
Mitapivat
AG-348
|
Pyruvate Kinase
|
Metabolic Disease
|
|
Mitapivat (AG-348) is an orally active pyruvate kinase allosteric activator. Mitapivat increases enzymatic activity, protein stability, and ATP levels over a broad range of PKLR genotypes, shows the potential to restore the activity of PK (pyruvate kinase)-deficient glycolytic pathways. Mitapivat can be used in study of PK deficiency.
|
-
- HY-W007686
-
-
- HY-110063
-
-
- HY-113067
-
|
Phytanic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease.
|
-
- HY-50159
-
-
- HY-112053
-
|
DPPH
2,2-Diphenyl-1-picrylhydrazyl
|
Others
|
Metabolic Disease
|
|
DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that can be used to measure the radical scavenging activity of antioxidants. The odd electron of nitrogen atom in DPPH is reduced by receiving a hydrogen atom from antioxidants to the corresponding hydrazine. DPPH method may be utilized in aqueous and nonpolar organic solvents and can be used to examine both hydrophilic and lipophilic antioxidants.
|
-
- HY-N8268
-
-
- HY-P2740
-
|
Alcohol dehydrogenase
EC 1.1.1.1
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Alcohol dehydrogenase is a dimeric protein in the cytosol of cells. Alcohol dehydrogenase, the key enzyme for alcohol consumption in the body, is the highest expressed in the liver and participates in the detoxification mechanism of environmental alcohol.
|
-
- HY-W050145S2
-
|
Levoglucosan-13C6
1,6-Anhydro-β-D-glucopyranose-13C6; 1,6-Anhydro-β-D-glucose-13C6
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Levoglucosan- 13C6 is the 13C labeled Levoglucosan[1]. Levoglucosan (1,6-Anhydro-β-D-glucopyranose) is an anhydrosugar produced through glucan pyrolysis and is widely found in nature[2].
|
-
- HY-133127A
-
-
- HY-110148
-
|
WWL113
|
Others
|
Metabolic Disease
|
|
WWL113 is a selective and orally active Ces3 and Ces1f inhibitor, with IC50 values of 120 nM and 100 nM for Ces3 and Ces1f, respectively. WWL113 appears to show excellent selectivity for the 60-kDa serine hydrolase (or hydrolases).
|
-
- HY-W013179S
-
-
- HY-16450
-
-
- HY-41417S6
-
|
Octanoic acid-d5
Caprylic acid-d5
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Octanoic acid-d5 is the deuterium labeled Octanoic acid[1]. Octanoic acid (Caprylic acid) is an oily liquid with a slightly unpleasant rancid taste and used commercially in the production of esters used in perfumery and also in the manufacture of dyes.
|
-
- HY-120904
-
|
AMPK-IN-1
|
AMPK
|
Metabolic Disease
|
|
AMPK-IN-1 is an activator of AMPK (EC50: 551 nM for isoform α2β2γ1). AMPK-IN-1 leads to eEF2 phosphorylation in a mTORC1-independent way.
|
-
- HY-151383
-
-
- HY-16708A
-
|
ZLN024 hydrochloride
|
AMPK
|
Metabolic Disease
|
|
ZLN024 hydrochloride is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1, AMPK α2β1γ1, AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC50s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.
|
-
- HY-P1790
-
|
Axltide
|
JAK
|
Metabolic Disease
|
|
Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989). Axltide is a substrate for Axl, DDR2, Mst1, and JAK2 kinases.
|
-
- HY-W012860S
-
-
- HY-W045271
-
-
- HY-N6959
-
|
Osmundacetone
|
Reactive Oxygen Species
Apoptosis
|
Metabolic Disease
|
|
Osmundacetone is a natural product isolated from Osmundae Rhizoma, with neuroprotective and anti-apoptotic effects. Osmundacetone has DPPH scavenging activity and protects neurological cell from oxidative stress. Osmundacetone can be a potential agent for the research of neurodegenerative diseases.
|
-
- HY-Y0504S1
-
-
- HY-145632
-
|
Pemvidutide
ALT-801
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research.
|
-
- HY-N10659
-
|
Praelolide
|
Keap1-Nrf2
NF-κB
|
Metabolic Disease
|
|
Praelolide is a potent Nrf2 activator. Praelolide suppresses osteoclastogenesis and reactive oxygen species (ROS) production. Praelolide disrupts Keap1-Nrf2 protein-protein interactions by noncovalent binding to Keap1. Praelolide has the potential for the research of osteoclastogenic bone disease.
|
-
- HY-W014504
-
-
- HY-122666
-
|
Org 25935
|
GlyT
|
Metabolic Disease
|
|
Org 25935 is a potent and selective glycine transporter 1 protein (GlyT1) inhibitor with an IC50 value of 100 nM. Org 25935 can decrease ethanol (EtOH) intake and EtOH preference in rats, whereas water intake is unaffected. Org 25935 can be used for researching alcohol dependence or abuse.
|
-
- HY-W042284
-
-
- HY-145458
-
-
- HY-19401
-
-
- HY-133804
-
-
- HY-18080
-
-
- HY-14472
-
|
Tesofensine
NS-2330
|
Dopamine Transporter
Serotonin Transporter
|
Metabolic Disease
|
|
Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent. Tesofensine is a CNS acting anti-obesity agent.
|
-
- HY-N0623S7
-
-
- HY-125857
-
-
- HY-50172
-
|
GPR120 modulator 2
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
GPR120 modulator 2 is a G protein coupled receptor 120 (GPR120) modulator extracted from patent US8394841B2, compound example F13. GPR120 modulator 2 can be used for the research of diseases associated with abnormal or deregulated GPR120, such as diabetes.
|
-
- HY-125012
-
|
MAP4K4-IN-3
|
MAP4K
|
Metabolic Disease
|
|
MAP4K4-IN-3 (Compound 17) is a potent and selective MAP4K4 inhibitor with an IC50 of 14.9 nM in kinase assay, an IC50 of 470 nM in cell assay. Antidiabetic agent.
|
-
- HY-N0486S12
-
-
- HY-32349S
-
-
- HY-117727S
-
|
Leriglitazone-d4
Hydroxypioglitazone-d4
|
PPAR
|
Metabolic Disease
|
|
Leriglitazone-d4 is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM[1].
|
-
- HY-104050
-
|
M-31850
|
Others
|
Metabolic Disease
|
|
M-31850 is a potent, selective and competitive β-hexosaminidase (Hex) inhibitor with IC50s of 6.0 µM and 3.1 µM for human HexA and human HexB, respectively. M-31850 also competitively inhibits β-N-acetyl-D-hexosaminidase OfHex2 with a Ki of 2.5 μM.
|
-
- HY-152184
-
-
- HY-N1423B
-
-
- HY-129770
-
|
D-Methionine sulfoxide
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-methionine sulfoxide is the D-isomer of Methionine sulfoxide. Methionine sulfoxide is an oxidation product of methionine. Methionine is the limiting amino acid in milk or leguminous proteins , which is easily oxidized during the course of storage or processing.
|
-
- HY-W014423S1
-
-
- HY-A0132S11
-
-
- HY-135383A
-
-
- HY-P0165
-
|
Taspoglutide
ITM077; R1583; BIM51077
|
GCGR
|
Metabolic Disease
|
|
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
|
-
- HY-149973
-
-
- HY-W013061S1
-
-
- HY-W021425
-
|
(2S,3R,4S,5R)-2-Amino-3,4,5,6-tetrahydroxyhexanal hydrochloride
|
Endogenous Metabolite
|
Metabolic Disease
|
|
(2S,3R,4S,5R)-2-Amino-3,4,5,6-tetrahydroxyhexanal hydrochloride is an endogenous metabolite.
|
-
- HY-119124
-
|
Edoxaban M4
D21-2393
|
Drug Metabolite
|
Metabolic Disease
|
|
Edoxaban M4, an active metabolite of Edoxaban, shows reproducible, but concentration-dependent matrix effects. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor .
|
-
- HY-143252
-
-
- HY-133680
-
|
β-Tocopherol
|
Tyrosinase
|
Metabolic Disease
|
|
β-Tocopherol is an analogue of vitamin E, exhibits antioxidant properties. β-Tocopherol can inhibit tyrosinase activity and melanin synthesis. β-Tocopherol also can prevent the inhibition of cell growth and of PKC activity caused by d-alpha-tocopherol.
|
-
- HY-P1731B
-
|
Tirzepatide hydrochloride
LY3298176 hydrochloride
|
GCGR
|
Metabolic Disease
|
|
Tirzepatide hydrochloride (LY3298176 hydrochloride) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that is being developed for the treatment of type 2 diabetes.
|
-
- HY-N2273
-
|
Gymnestrogenin
|
LXR
|
Metabolic Disease
|
|
Gymnestrogenin is a pentahydroxytriterpene from the leaves of Gymnema sylvestre R.Br. Gymnestrogenin is a LXR antagonist with IC50s of 2.5 and 1.4 μM for LXRα and LXRβ transactivation, respectively. Gymnestrogenin reduces the transcriptional activity of LXR even on its own promoter, thus reducing the mRNA expression.
|
-
- HY-P4805
-
-
- HY-151591
-
|
SPAA-52
|
Phosphatase
|
Metabolic Disease
|
|
SPAA-52 is an orally active, competitive and reversible low-molecular-weight protein tyrosine phosphatase (LMW-PTP) inhibitor (IC50=4 nM, Ki=1.2 nM). SPAA-52 can be used in diabete research.
|
-
- HY-134194
-
|
KL201
|
Others
|
Metabolic Disease
|
|
KL201 a circadian clock modulator, is a isoform-selective cryptochrome 1 (CRY1) stabilizer. KL201 has no stabilizing effect on CRY2. KL201 lengthens the period of circadian rhythms in cells and tissues.
|
-
- HY-113432S
-
|
Nudifloramide-d3
|
Endogenous Metabolite
PARP
|
Metabolic Disease
|
|
Nudifloramide-d3 (2PY-d3) is the deuterium labeled Nudifloramide. Nudifloramide (2PY) is one of the end products of nicotinamide-adenine dinucleotide (NAD) degradation. Nudifloramide significantly inhibits poly(ADP-ribose) polymerase (PARP-1) activity in vitro[1].
|
-
- HY-112598
-
|
PF-06815345
|
Ser/Thr Protease
|
Metabolic Disease
|
|
PF-06815345 is an orally active and potent inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9) with an IC50 value of 13.4 μM. PF-06815345 significantly decreases the PCSK9 level in vivo in mouse.
|
-
- HY-W011982
-
-
- HY-W015954
-
-
- HY-107863
-
-
- HY-N1425
-
|
Tiliroside
|
Others
|
Metabolic Disease
|
|
Tiliroside, a glycosidic flavonoid, possesses anti-diabetic activities. Tiliroside is a noncompetitive inhibitor of α-amylase with a Ki value of 84.2 μM. Tiliroside inhibits carbohydrate digestion and glucose absorption in the gastrointestinal tract.
|
-
- HY-N8522
-
-
- HY-B2203
-
-
- HY-19937A
-
|
Saroglitazar magnesium
|
PPAR
|
Metabolic Disease
|
|
Saroglitazar magnesium is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC50 values of 0.65 pM and 3 nM in HepG2 cells, respectively.
|
-
- HY-P2080B
-
|
GIP (1-30) amide,human acetate
|
Insulin Receptor
|
Metabolic Disease
|
|
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 -9-10 -6 M.
|
-
- HY-Y0504S2
-
-
- HY-125556
-
|
Tetragastrin
Cholecystokinin tetrapeptide; CCK-4
|
Cholecystokinin Receptor
|
Metabolic Disease
|
|
Tetragastrin (Cholecystokinin tetrapeptide; CCK-4) is the C-terminal tetrapeptide of gastrin. Tetragastrin can stimulate gastric secretion. Tetragastrin is a Cholecystokinin (CCK-4) receptor agonist. Gastric mucosal protection.
|
-
- HY-101449
-
-
- HY-77641S
-
|
Cinnamoylglycine-d2
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Cinnamoylglycine-d2 is the deuterium labeled Cinnamoylglycine. Cinnamoylglycine is a glycine conjugate of cinnamic acid and a urinary metabolite in human. Cinnamoylglycine is used as a potential urinary biomarker indicating intact or disrupted colonization resistance during and after antibiotic treatment[1].
|
-
- HY-N7202
-
-
- HY-143239
-
|
PPARα/γ agonist 1
|
PPAR
|
Metabolic Disease
|
|
PPARα/γ agonist 1 is a potent and dual PPARα/γ partial agonist with EC50 values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research.
|
-
- HY-100396
-
-
- HY-12841
-
|
KHK-IN-1
|
Others
|
Metabolic Disease
|
|
KHK-IN-1 (compound 8) is a selective and cell membrane permeable ketohexokinase (KHK) inhibitor (IC50=12 nM; F=34%). KHK-IN-1 inhibits the production of F1P in HepG2 cell lysates (IC>sub>50=400 nM). KHK-IN-1 has potential for the study of diabetes and obesity.
|
-
- HY-19264
-
-
- HY-N4174
-
-
- HY-113453
-
-
- HY-W250154
-
|
β-Nicotinamide adenine dinucleotide reduced dipotassium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
β-Nicotinamide adenine dinucleotide reduced dipotassium is an orally active reduced coenzyme. β-Nicotinamide adenine dinucleotide reduced dipotassium is a donor of ADP-ribose units in ADP-ribosylaton reactions and a precursor of cyclic ADP-ribose. β-Nicotinamide adenine dinucleotide reduced dipotassium plays a role as a regenerative electron donor in cellular energy metabolism, including glycolysis, β-oxidation and the tricarboxylic acid (TCA) cycle.
|
-
- HY-N4135
-
-
- HY-N7668
-
-
- HY-N10407
-
-
- HY-119919
-
-
- HY-N2424
-
-
- HY-128754
-
-
- HY-B0765
-
-
- HY-N2097
-
-
- HY-A0132S2
-
-
- HY-117727A
-
|
Leriglitazone hydrochloride
Hydroxypioglitazone hydrochloride
|
PPAR
|
Metabolic Disease
|
|
Leriglitazone (Hydroxypioglitazone) hydrochloride, a metabolite of pioglitazone. Leriglitazone (Hydroxypioglitazone) hydrochloride PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Leriglitazone (Hydroxypioglitazone) hydrochloride binds to the PPARγ C-terminal ligand-binding domain (LBD) with a Ki of 1.2 μM，Leriglitazone induces transcriptional efficacy of the PPARγ (LBD) with an EC50 of 680 nM.
|
-
- HY-W013049S1
-
-
- HY-N4179
-
-
- HY-N0230S1
-
|
β-Alanine-15N
2-Carboxyethylamine-15N; 3-Aminopropanoic acid-15N
|
Endogenous Metabolite
|
Metabolic Disease
|
|
β-Alanine- 15N is the 15N-labeled β-Alanine. β-Alanine is a non-essential amino acid that is shown to be metabolized into carnosine, which functions as an intracellular buffer.
|
-
- HY-16343C
-
|
NB-598 Maleate
|
Others
|
Metabolic Disease
|
|
NB-598 Maleate is a potent and competitive inhibitor of squalene epoxidase (SE), and suppresses triglyceride biosynthesis through the farnesol pathway.
|
-
- HY-138429
-
|
COQ7-IN-2
|
Others
|
Metabolic Disease
|
|
COQ7-IN-2 (compound 12) is an inhibitor of COQ7, witn IC50 values of 7.3 μM and 15.4 μM for DMQ10 and UQ10 accumulation, respectively.
|
-
- HY-134427
-
|
Palmitoyl coenzyme A lithium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Palmitoyl coenzyme A lithium is an acyl-CoA thioester that can be transported into the mitochondrial matrix via the carnitine shuttle system and is involved in β-oxidation. Palmitoyl coenzyme A lithium can also be used as a substrate for sphingosine biosynthesis.
|
-
- HY-135212
-
-
- HY-W014423S7
-
-
- HY-D1445
-
|
LysoSensor PDMPO
|
Fluorescent Dye
|
Metabolic Disease
|
|
PDMPO, a lysosome pH indicator, is an excellent fluorescent acidotropic reagent for fluorescence imaging. PDMPO is a potent tool with which to study acidic organelles of live cells. PDMPO exhibits pH-dependent dual-excitation and dual-emission spectral peaks. PDMPO produces a blue fluorescence in weakly acidic organelles and shifts to yellow in more acidic lysosomes (Abs=329 nm; Em=440 nm).
|
-
- HY-P3504
-
|
Efinopegdutide
JNJ-64565111; HM12525A
|
GCGR
iGluR
|
Metabolic Disease
|
|
Efinopegdutide (JNJ-64565111) is a potent dual glucagon-like peptide-1 (GLP-1)/glucagon receptor (GluR) agonist, which activates both the GLP-1 and glucagon receptors. Efinopegdutide can be used in research of nonalcoholic steatohepatitis (NASH).
|
-
- HY-128978
-
-
- HY-13749S1
-
-
- HY-B2227BS3
-
|
Lactate-13C-1 sodium
Lactic acid-13C-1 sodium
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
|
Lactate- 13C-1 (sodium) is the 13C labeled Lactate (sodium)[1]. Lactate (Lactic acid) sodium is the product of glycogenolysis and glycolysis. Lactate (Lactic acid) sodium functions in a variety of biochemical processes[2].
|
-
- HY-N1967
-
|
Dihydrocurcumin
|
Fatty Acid Synthase (FASN)
|
Metabolic Disease
|
|
Dihydrocurcumin, a major metabolites of curcumin, reduces lipid accumulation and oxidative stress. Dihydrocurcumin regulates mRNA and protein expression levels of SREBP-1C, PNPLA3 and PPARα, increases protein expression levels of pAKT and PI3K, and reduced the levels of cellular NO and ROS via Nrf2 signaling pathways.
|
-
- HY-P1144A
-
-
- HY-14658B
-
|
(R)-Thalidomide
(R)-(+)-Thalidomide
|
Others
|
Metabolic Disease
|
|
(R)-Thalidomide ((R)-(+)-Thalidomide) is the R-enantiomer of Thalidomide. (R)-Thalidomide has psychomotor stabilizing properties.
|
-
- HY-147168
-
-
- HY-Y1009
-
-
- HY-34516
-
-
- HY-150244
-
|
SLU-PP-915
|
Estrogen Receptor/ERR
|
Metabolic Disease
|
|
SLU-PP-915 is an agonist of ERR. SLU-PP-915 has an EC50 value of approximately 400 nM for ERRα, ERRβ, and ERRγ. SLU-PP-915 has potential application in maintaining oxidative metabolism and heart failure.
|
-
- HY-126225
-
-
- HY-151973
-
-
- HY-W008915
-
|
Cytidine 5'-diphosphate trisodium salt
CDP
|
DNA/RNA Synthesis
|
Metabolic Disease
|
|
Cytidine 5'-diphosphate trisodium salt (CDP) is produced by the transfer of phosphoryl group from ATP to cytidine monophosphate (CMP) catalyzed by uridine monophosphate kinase (UMPK). Cytidine 5′-diphosphate can be used to produce Cytidine triphosphate (CTP) for synthesis of DNA and RNA.
|
-
- HY-B0511
-
|
Biotin
Vitamin B7; Vitamin H; D-Biotin
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Biotin (Vitamin B7) is a water-soluble B vitamin and serves as a coenzyme for five carboxylases in humans, involved in the synthesis of fatty acids, isoleucine, and valine, and in gluconeogenesis. Biotin is necessary for cell growth, the production of fatty acids, and the metabolism of fats and amino acids.
|
-
- HY-121827
-
|
LH21
|
Cannabinoid Receptor
|
Metabolic Disease
|
|
LH-21 is a potent in vivo neutral cannabinoid CB1 receptor antagonist. LH-21 reduces food intake and body weight gain in obese Zucker rats.
, and displays efficacy as a feeding inhibitor.
|
-
- HY-17399
-
|
Racecadotril
Acetorphan
|
Neprilysin
|
Metabolic Disease
|
|
Racecadotril (Acetorphan) is a neutral endopeptidase (NEP) inhibitor. Racecadotril and its active metabolite Thiorphan inhibits purified NEP activity from mouse brain with Kis of 4500 and 6.1 nM, , respectively. Antidiarrheal agent.
|
-
- HY-114557
-
-
- HY-126144A
-
|
(E/Z)-GSK-3β inhibitor 1
|
GSK-3
|
Metabolic Disease
|
|
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC50 of 4.9 nM.
|
-
- HY-W011727S
-
-
- HY-W010861
-
-
- HY-B1726
-
|
Phenacaine
Holocaine
|
Phosphodiesterase (PDE)
|
Metabolic Disease
|
|
Phenacaine (Holocaine) is a local anesthetic. Phenacaine inhibits the specific calmodulin-dependent stimulation of erythrocyte Ca 2+-ATPase and cyclic nucleotide phosphodiesterases from brain and heart.
|
-
- HY-Y1819
-
-
- HY-101082
-
-
- HY-123039
-
|
CP-532623
|
CETP
|
Metabolic Disease
|
|
CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties.
|
-
- HY-16708
-
|
ZLN024
|
AMPK
|
Metabolic Disease
|
|
ZLN024 is an AMPK allosteric activator. ZLN024 directly activates recombinant AMPK α1β1γ1, AMPK α2β1γ1, AMPK α1β2γ1 and AMPK α2β2γ1 heterotrimer with EC50s of 0.42 µM, 0.95 µM, 1.1 µM and 0.13 µM, respectively.
|
-
- HY-N0022
-
|
Isoacteoside
Isoverbascoside
|
Others
|
Metabolic Disease
|
|
Isoacteoside is a natural compound which exhibit significant inhibition of advanced glycation end product formation with IC50 values of 4.6-25.7 μM, compared with those of aminoguanidine (IC50=1,056 μM) and quercetin (IC50=28.4 μM) as positive controls.
|
-
- HY-W011063
-
|
Gly-Phe-β-naphthylamide
|
Cathepsin
|
Metabolic Disease
|
|
Gly-Phe-β-naphthylamide is the substrate of Cathepsin C. Gly-Phe-β-naphthylamide can be used to study intralysosomal hydrolysis, lysosomal membrane permeability, and the function of cathepsin C.
|
-
- HY-128933
-
-
- HY-19715
-
-
- HY-116175
-
|
BIBB 515
|
Others
|
Metabolic Disease
|
|
BIBB 515 is a potent, selective and orally active 2,3-oxidosqualene cyclase (OSC) inhibitor with ED50 values of 0.2-0.5 mg/kg and 0.36-33.3 mg/kg in rats and mice (1-5 hours), respectively. BIBB 515 exerts lipid-lowering effect mainly by inhibiting the production of low-density lipoprotein (LDL).
|
-
- HY-B1045
-
-
- HY-66054
-
-
- HY-112920
-
|
TM-25659
|
Others
|
Metabolic Disease
|
|
TM-25659 is a transcriptional co-activator with PDZ-binding motif (TAZ) modulator. Anti-osteoporotic and anti-obesity activities.
|
-
- HY-117621A
-
|
PF-04634817 succinate
|
CCR
|
Metabolic Disease
|
|
PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC50=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC50=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy.
|
-
- HY-W014225
-
-
- HY-135878
-
-
- HY-113273A
-
|
Diadenosine pentaphosphate pentasodium
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Diadenosine pentaphosphate pentasodium is an endogenous vasoactive purine dinucleotide which has been isolated from thrombocytes. Diadenosine polyphosphates (ApnA, n=2–7) have been identified as constituents of secretory vesicles such as in platelets, chromaffin cells, Torpedo synaptic terminals and brain synaptosomes.
|
-
- HY-W011848S
-
|
Monobenzyl phthalate-d4
2-((Benzyloxy)carbonyl)benzoic acid-d4
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Monobenzyl phthalate-d4 is the deuterium labeled Monobenzyl phthalate. Monobenzyl phthalate (2-((Benzyloxy)carbonyl)benzoic acid) is the urinary metabolite exposuring to phthalates, such as, diethylhexyl phthalate (DEHP)[1].
|
-
- HY-147257
-
|
Cofrogliptin
HSK7653
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 diabetes mellitus (T2DM) .
|
-
- HY-16007
-
|
(-)-Hydroxycitric acid
Garcinia acid
|
ATP Citrate Lyase
|
Metabolic Disease
|
|
(-)-Hydroxycitric acid (Garcinia acid) is the principal acid of fruit rinds of Garcinia cambogia. (-)-Hydroxycitric acid is a potent and competitive inhibitor of ATP citrate lyase. (-)-Hydroxycitric acid suppresses the fatty acid synthesis, lipogenesis, food intake, and induced weight loss.
|
-
- HY-N0419
-
-
- HY-40161
-
-
- HY-B0389A
-
|
D-Glucose-13C6
Glucose-13C6; D-(+)-Glucose-13C6; Dextrose-13C6
|
Endogenous Metabolite
|
Metabolic Disease
|
|
D-Glucose- 13C6 is a tracer used to trace glucose-related synthetic catabolism, is a low-cost alternative with the significant advantage that the sixth isotope of natural glucose has virtually zero natural abundance, which facilitates isotopomer analysis with <1% labeled glucose in the infusate[1][2].
|
-
- HY-W404002
-
|
BR102910
|
Prolyl Endopeptidase (PREP)
|
Metabolic Disease
|
|
BR102910 is a selective fibroblast activation protein (FAP) inhibitor with the IC50 of 2 nM. BR102910 also inhibits prolyl oligopeptidase (PREP) with the IC50 of 49.00 μM. BR102910 can be used for the researchof type 2
|
-
- HY-Y0267
-
-
- HY-E70057
-
|
alpha-2,8-Sialyltransferase (CstII)
ST8Sia VI; GD3 synthase
|
Endogenous Metabolite
|
Metabolic Disease
|
|
alpha-2,8-Sialyltransferase (CstII) (ST8Sia VI) is a member of alpha2,8-sialyltransferase (ST8Sia) family, is often used in biochemical studies. alpha-2,8-Sialyltransferase (CstII) catalyzes elongation of the α2,8-linked oligo/polysialic acid chain on the Sia residue transferred.
|
-
- HY-N1993
-
-
- HY-N0324S2
-
|
Cholic acid-13C
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Cholic acid- 13C is the 13C-labeled Cholic acid. Cholic acid is a major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
|
-
- HY-W014233
-
-
- HY-122025
-
|
AC-262536
|
Androgen Receptor
|
Metabolic Disease
|
|
AC-262536 is a selective and non-steroidal androgen receptor modulators (SARMs) with beneficial anabolic effects. AC-262536 exhibits potent agonist activity at the androgen receptor, with an affinity in the low nanomolar range (1-10 nM).
|
-
- HY-W019724
-
-
- HY-14147
-
|
Renzapride
BRL 24924
|
5-HT Receptor
|
Metabolic Disease
|
|
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study.
|
-
- HY-108742
-
|
Abaloparatide
BA 058; BIM 44058
|
Thyroid Hormone Receptor
Arrestin
|
Metabolic Disease
|
|
Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis.
|
-
- HY-E70058
-
-
- HY-P2879
-
|
Cholesterol esterase
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Cholesterol esterase is an enzyme that hydrolyzes cholesterol ester to cholesterol and free fatty acid in the intestinal lumen. Cholesterol synthesized in the acinar cells and is stored in zymogen granules. Cholesterol esterase is also known as bile salt-stimulated lipase and carboxy ester lipasea, acts function for acceleration of cholesterol absorption.
|
-
- HY-151144
-
-
- HY-13995B
-
|
Sevelamer carbonate
|
Others
|
Metabolic Disease
|
|
Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995).
|
-
- HY-W014125
-
-
- HY-126995
-
-
- HY-144429
-
|
TRPC5-IN-4
|
TRP Channel
|
Metabolic Disease
|
|
TRPC5-IN-4 is potent and safe TRPC inhibitor with IC50 value of 14.07 nM and 65 nM for TRPC5 and TRPC4, respectively. TRPC5-IN-4 shows no damage on the cellular component of liver and kidney. TRPC5-IN-4 can be used for the research of chronic kidney disease (CKD).
|
-
- HY-126326
-
|
SWE101
|
Epoxide Hydrolase
|
Metabolic Disease
|
|
SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC50s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH.
|
-
- HY-P1747
-
|
Pneumadin, rat
PNM
|
Others
|
Metabolic Disease
|
|
Pneumadin, rat (PNM) is a decapeptide, which possess a potent stimulating effect on arginine-vasopressin (AVP) release. Pneumadin, rat (PNM) exerts a marked antidiuretic effect in animals with functional AVP system.
|
-
- HY-128417S3
-
-
- HY-153497A
-
|
Vupanorsen sodium
IONIS ANGPT-L3Rx sodium; ISIS 703802 sodium
|
Others
|
Metabolic Disease
|
|
Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.
|
-
- HY-W015782
-
|
4-Ethylresorcinol
|
Others
|
Metabolic Disease
|
|
4-Ethylresorcinol, a derivative of resorcinol, can act as substrates of tyrosinase. 4-Ethylresorcinol possess hypopigmentary effects. 4-Ethylresorcinol attenuates mRNA and protein expression of tyrosinase-related protein (TRP)-2, and possessed antioxidative effect by inhibiting lipid peroxidation.
|
-
- HY-N9326
-
|
Uralenol
|
Phosphatase
|
Metabolic Disease
|
|
Uralenol is a natural PTP1B inhibitor (IC50=21. 5 μM) from Broussonetia papyrifera. PTP1B have been shown to play a major role in the dephosphorylation of the insulin receptor in many cellular and biochemical studies.
|
-
- HY-135335S
-
-
- HY-N11660
-
|
weak Hepatoprotective agent-1
|
Others
|
Metabolic Disease
|
|
weak Hepatoprotective agent-1 (Compound 11) is a natural product that can be isolated from the fruits of Arctium lappa L.. weak Hepatoprotective agent-1 exhibits weak hepatoprotective activities at a concentration of 10 μM.
|
-
- HY-103546
-
|
BETP
|
GCGR
|
Metabolic Disease
|
|
BETP is an agonist of glucagon-like peptide-1 (GLP-1) receptor, with EC50s of 0.66 and 0.755 μM for human and rat GLP-1 receptor, respectively.
|
-
- HY-113283
-
-
- HY-P3186
-
|
Glucose dehydrogenase (GDH)
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Glucose dehydrogenase (GDH) is a oxidoreductase. Glucose dehydrogenase (GDH) catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP + to NADPH or, to a lesser extent, NAD + to NADH. Glucose dehydrogenase (GDH) accepts both NAD + and NADP + as cofactors and can be used for the regeneration of NADH and NADPH.
|
-
- HY-50691
-
-
- HY-P2426
-
-
- HY-W017464
-
|
NAPQI
|
Endogenous Metabolite
|
Metabolic Disease
|
|
NAPQI is the toxic metabolite of Acetaminophen (HY-66005). NAPQI is also an inhibitor of enzymes in the vitamin K cycle. NAPQI is rapidly detoxified by glutathione (GSH), but in situations of GSH deficiency, excess NAPQI reacts with cysteine residues in proteins, causing cell death and toxicity in the liver.
|
-
- HY-16082
-
|
AZD7545
|
PDHK
|
Metabolic Disease
|
|
AZD7545 is a potent, competitive, selective PDHK2 (pyruvate dehydrogenase kinase 2) inhibitor with IC50s of 36.8 nM, 6.4 nM for PDHK1 and PDHK2, respectively.
|
-
- HY-10449
-
|
Luseogliflozin
TS 071
|
SGLT
|
Metabolic Disease
|
|
Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes.
|
-
- HY-110267
-
|
DY268
|
FXR
|
Metabolic Disease
|
|
DY268 is a farnesoid X receptor (FXR) antagonist (IC50=7.5 nM in a time-resolved FRET assay). It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM.
|
-
- HY-143312D
-
|
(R)-V-0219 hydrochloride
|
GLP Receptor
|
Metabolic Disease
|
|
(R)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R.
|
-
- HY-106405
-
|
Nebicapone
BIA 3-202
|
COMT
|
Metabolic Disease
|
|
Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease.
|
-
- HY-114566
-
-
- HY-W040268S
-
-
- HY-105286
-
|
BI-135585
|
11β-HSD
|
Metabolic Disease
|
|
BI-135585 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) inhibitor with an IC50 of 13 nM. BI-135585 exhibits >1000-fold selectivity over other hydroxysteroid dehydrogenases. BI-135585 can be used for type 2 diabetes research.
|
-
- HY-107641
-
|
α-Cyano-4-hydroxycinnamic acid
α-Cyano-4-hydroxycinnamate
|
Monocarboxylate Transporter
|
Metabolic Disease
|
|
α-Cyano-4-hydroxycinnamic acid (α-Cyano-4-hydroxycinnamate) is a potent and non-competitive inhibitor of monocarboxylate transporters (MCTs). α-Cyano-4-hydroxycinnamic acid inhibits mitochondrial pyruvate transporter with a Ki of 6.3 μM. α-Cyano-4-hydroxycinnamic acid is used as a matrix to facilitate peptide ionization in matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry applications.
|
-
- HY-113044
-
-
- HY-128737
-
-
- HY-N0327
-
|
Lobetyolin
|
Apoptosis
Xanthine Oxidase
|
Metabolic Disease
|
|
Lobetyolin, a bioactive compound, is derived from Codonopsis pilosula. Lobetyolin has anti-inflammatory, anti-oxidative and xanthine oxidase inhibiting activities. Lobetyolin also induces the apoptosis via the inhibition of ASCT2-mediated glutamine metabolism.
|
-
- HY-131334
-
|
AMPK activator 4
|
AMPK
|
Metabolic Disease
|
|
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect.
|
-
- HY-N4243
-
|
Neocurdione
|
Others
|
Metabolic Disease
|
|
Neocurdione is a hepatoprotective sesquiterpene isolated from Curcuma zedoaria rhizome. Neocurdione exerts potent effect on D-galactosamine- (D-Gain) and lipopolysaccharide- (LPS) induced acute liver injury in mice.
|
-
- HY-Y1809S1
-
-
- HY-N2362S5
-
|
DL-Alanine-15N
DL-2-Aminopropionic acid-15N
|
Endogenous Metabolite
|
Metabolic Disease
|
|
DL-Alanine- 15N is the 15N labeled DL-Alanine[1]. DL-alanine, an amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine, and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver[2][3][4][5][6][7].
|
-
- HY-113239S
-
-
- HY-14413
-
|
SR3335
ML 176
|
ROR
|
Metabolic Disease
|
|
SR3335 (ML 176) is a selective RORα inverse agonist that directly binds to RORα with a Ki of 220 nM.
|
-
- HY-149276
-
|
SLC26A3-IN-2
|
GLUT
|
Metabolic Disease
|
|
SLC26A3-IN-2 is an orally active inhibitor of anion exchanger protein SLC26A3 (IC50=360 nM). SLC26A3 belongs to solute carrier (SLC) proteins, and the SLC26 family. SLC26 family has broad anion specificity for chloride, bicarbonate, sulfate and oxalate. SLC26A3 down-regulates in adenoma, DRA, involves in in intestinal absorption of chloride and oxalate. The loss of SLC26A3 function mutations is associated with chloride-losing diarrhea.
|
-
- HY-W017113
-
-
- HY-E70053
-
-
- HY-N11448
-
-
- HY-B0445S1
-
-
- HY-N7452
-
-
- HY-23195
-
-
- HY-113067S
-
|
Phytanic acid-d3
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Phytanic acid-d3 is the deuterium labeled Phytanic acid[1]. Phytanic acid is an endogenous metabolite present in Blood that can be used for the research of Zellweger Syndrome, Alpha Methylacyl CoA Racemase Deficiency, Rhizomelic Chondrodysplasia Punctata and Infantile Refsum Disease[2][3][4][5][6].
|
-
- HY-23497
-
-
- HY-N2511
-
-
- HY-118743
-
|
KMN-80
|
Prostaglandin Receptor
|
Metabolic Disease
|
|
KMN-80, a derivative of PGE1 (HY-B0131), is a selective and potent agonist of EP4 receptor with an IC50 and a Ki of 3 nM and 2.35 nM, respectively. KMN-80 is against EP3 receptor with an IC50 of 1.4 μM and >10 μM for all other prostanoid receptors.
|
-
- HY-N4254
-
-
- HY-146412
-
-
- HY-W014589
-
-
- HY-15331
-
|
VD3-d6
Vitamin D3-26,26,26,27,27,27-d6
|
VD/VDR
|
Metabolic Disease
|
|
VD3-d6 is the deuterium labeled Vitamin D3; tools for determination of Vitamin D3 metabolites in human serum.
|
-
- HY-W016734
-
-
- HY-U00360
-
-
- HY-B1613A
-
-
- HY-113371
-
|
2-Methylcitric acid
Methylcitric acid
|
Endogenous Metabolite
|
Metabolic Disease
|
|
2-Methylcitric acid (Methylcitric acid) is an endogenous metabolite in the 2-methylcitric acid cycle. 2-Methylcitric acid accumulates in methylmalonic and propionic acidemias and acts as a marker metabolite. 2-Methylcitric acid markedly inhibits ADP-stimulated and uncoupled respiration in mitochondria supported by glutamate.
|
-
- HY-144117
-
|
GFB-12811
|
CDK
|
Metabolic Disease
|
|
GFB-12811 is a high selective and orally active CDK5 inhibitor with an IC50 of 2.3 nM. GFB-12811 is highly selective over the other tested kinases (CDK1/2/6/7/9).
|
-
- HY-132841
-
-
- HY-100793
-
|
SR12813
GW 485801
|
HMG-CoA Reductase (HMGCR)
Autophagy
|
Metabolic Disease
|
|
SR12813 (GW 485801) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM. SR12813 is also an efficient agonist of human pregnane X receptor (hPXR). SR12813 can strongly bind to hPXR but not to mouse PXR (mPXR).
|
-
- HY-W015675
-
-
- HY-D1046
-
-
- HY-W001132
-
-
- HY-A0124
-
|
Sapropterin
(6R)-BH4; (6R)-Tetrahydro-L-biopterin
|
Others
|
Metabolic Disease
|
|
Sapropterin ((6R)-BH4) is an orally active phenylalanine hydroxylase (PAH) cofactor, which is effective in reducing blood phenylalanine concentrations. Sapropterin can be used in study of phenylketonuria (PKU).
|
-
- HY-148922
-
|
PPARα/γ agonist 2
|
PPAR
|
Metabolic Disease
|
|
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent.
|
-
- HY-18173
-
|
AZD8329
|
11β-HSD
|
Metabolic Disease
|
|
AZD8329 is a potent 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor with an IC50 of 9 nM for human 11β-HSD1, displays excellent selectivity versus 11β-HSD2, 17β-HSD1 and 17β-HSD3.
|
-
- HY-N0486S7
-
-
- HY-U00141
-
|
ABTL-0812
α-Hydroxylinoleic acid
|
Autophagy
|
Metabolic Disease
|
|
ABTL-0812 (α-Hydroxylinoleic acid) induces endoplasmic reticulum (ER) stress-mediated autophagy. ABTL-0812 is a first-in-class small molecule with anti-cancer activity.
|
-
- HY-110179
-
-
- HY-W014787S
-
|
Decanedioic acid-d4
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Decanedioic acid-d4 is the deuterium labeled Decanedioic acid[1]. Decanedioic acid, a normal urinary acid, is found to be associated with carnitine-acylcarnitine translocase deficiency and medium chain acyl-CoA dehydrogenase deficiency[2].
|
-
- HY-139066
-
|
Punicic acid
Trichosanic acid
|
Others
|
Metabolic Disease
|
|
Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and a ω-5 polyunsaturated fatty acid. Punicic acid has the potential for the research of various chronic diseases.
|
-
- HY-N10360
-
|
Ellipyrone A
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
|
Ellipyrone A, a γ-pyrone enclosed macrocyclic poyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.35 mM). Ellipyrone A also has anti-carbolytic property against α-glucosidase (IC50=0.74 mM) and α-amylase (IC50=0.59 mM).
|
-
- HY-P4157
-
-
- HY-A0020S
-
|
Eldecalcitol-d6
|
VD/VDR
|
Metabolic Disease
|
|
Eldecalcitol-d6 is the deuterium labeled Eldecalcitol. Eldecalcitol is an orally active analogue of active vitamin D used in the treatment of osteoporosis.
|
-
- HY-P99816
-
-
- HY-144718
-
|
PTP1B-IN-17
|
Phosphatase
|
Metabolic Disease
|
|
PTP1B-IN-17 (Compound 45), a potential selective benzimidazole derivative, acts as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with a Ki of 30.2 μM. PTP1B-IN-17 can be used for the research of type 2 diabetes.
|
-
- HY-N0324B
-
-
- HY-D0844
-
-
- HY-W016798
-
-
- HY-W004078
-
-
- HY-B2134
-
|
Casanthranol
|
Others
|
Metabolic Disease
|
|
Casanthranol is a concentrated mixture of anthranol glycosides from cascara sagrada (dried bark of Rhamnus p.) and used as a laxative in constipation and various medical conditions, stimulant laxative Casanthranol encourages bowel movements by acting on the intestinal wall to increase muscle contractions.
|
-
- HY-D0889
-
-
- HY-135391
-
-
- HY-N0486S11
-
-
- HY-128741
-
-
- HY-128434
-
-
- HY-N0215S11
-
|
L-Phenylalanine-13C9,15N
(S)-2-Amino-3-phenylpropionic acid-13C9,15N
|
Calcium Channel
iGluR
Endogenous Metabolite
|
Metabolic Disease
|
|
L-Phenylalanine- 13C9, 15N is the 13C- and 15N-labeled L-Phenylalanine. L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals[1][2][3][4].
|
-
- HY-135391S
-
|
Ezetimibe phenoxy glucuronide-d4
Ezetimibe glucuronide-d4; Ezetimibe β-D-glucuronide-d4
|
Drug Metabolite
|
Metabolic Disease
|
|
Ezetimibe phenoxy glucuronide-d4 is the deuterium labeled Ezetimibe phenoxy glucuronide. Ezetimibe phenoxy glucuronide is the active metabolite of Ezetimibe. Antihyperlipoproteinemic activity[1]. Ezetimibe is a potent cholesterol absorption inhibitor[2].
|
-
- HY-W015466
-
-
- HY-135586
-
-
- HY-150560
-
|
α-Glucosidase-IN-11
|
Glucosidase
|
Metabolic Disease
|
|
α-Glucosidase-IN-11 is a highly permeable competitive α-glucosidase inhibitor with the IC50 value of 0.56 μM. α-Glucosidase-IN-11 binds to Trp residues in α-glucosidase and regulates protein folding. α-Glucosidase-IN-11 can be used to regulate blood glucose levels.
|
-
- HY-B1674S
-
-
- HY-129707
-
|
AMG 837 hemicalcium
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
|
AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 hemicalcium inhibits specific [ 3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents.
|
-
- HY-112169A
-
-
- HY-N2025
-
|
Oroxin A
|
PPAR
Glucosidase
|
Metabolic Disease
|
|
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity. Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence.
|
-
- HY-Y0479S
-
-
- HY-12831
-
-
- HY-147718
-
-
- HY-N0122
-
-
- HY-129834
-
-
- HY-N9536
-
|
Cinnamtannin A2
|
GLP Receptor
|
Metabolic Disease
|
|
Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exh |
